<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1257" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1257/" /><meta name="ncbi_pagename" content="Multiple Endocrine Neoplasia Type 2 - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Multiple Endocrine Neoplasia Type 2 - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Multiple Endocrine Neoplasia Type 2" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/08/15" /><meta name="citation_author" content="Charis Eng" /><meta name="citation_pmid" content="20301434" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1257/" /><meta name="citation_keywords" content="MEN 2" /><meta name="citation_keywords" content="MEN 2 Syndrome" /><meta name="citation_keywords" content="MEN 2 Syndrome" /><meta name="citation_keywords" content="Multiple Endocrine Neoplasia Type 2A (MEN 2A)" /><meta name="citation_keywords" content="Multiple Endocrine Neoplasia Type 2B (MEN 2B)" /><meta name="citation_keywords" content="Familial Medullary Thyroid Carcinoma (FMTC)" /><meta name="citation_keywords" content="Proto-oncogene tyrosine-protein kinase receptor ret" /><meta name="citation_keywords" content="RET" /><meta name="citation_keywords" content="Multiple Endocrine Neoplasia Type 2" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Multiple Endocrine Neoplasia Type 2" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Charis Eng" /><meta name="DC.Date" content="2019/08/15" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1257/" /><meta name="description" content="Multiple endocrine neoplasia type 2 (MEN 2) includes the following phenotypes: MEN 2A, FMTC (familial medullary thyroid carcinoma, which may be a variant of MEN 2A), and MEN 2B. All three phenotypes involve high risk for development of medullary carcinoma of the thyroid (MTC); MEN 2A and MEN 2B involve an increased risk for pheochromocytoma; MEN 2A involves an increased risk for parathyroid adenoma or hyperplasia. Additional features in MEN 2B include mucosal neuromas of the lips and tongue, distinctive facies with enlarged lips, ganglioneuromatosis of the gastrointestinal tract, and a marfanoid habitus. MTC typically occurs in early childhood in MEN 2B, early adulthood in MEN 2A, and middle age in FMTC." /><meta name="og:title" content="Multiple Endocrine Neoplasia Type 2" /><meta name="og:type" content="book" /><meta name="og:description" content="Multiple endocrine neoplasia type 2 (MEN 2) includes the following phenotypes: MEN 2A, FMTC (familial medullary thyroid carcinoma, which may be a variant of MEN 2A), and MEN 2B. All three phenotypes involve high risk for development of medullary carcinoma of the thyroid (MTC); MEN 2A and MEN 2B involve an increased risk for pheochromocytoma; MEN 2A involves an increased risk for parathyroid adenoma or hyperplasia. Additional features in MEN 2B include mucosal neuromas of the lips and tongue, distinctive facies with enlarged lips, ganglioneuromatosis of the gastrointestinal tract, and a marfanoid habitus. MTC typically occurs in early childhood in MEN 2B, early adulthood in MEN 2A, and middle age in FMTC." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1257/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/men2/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1257/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8BAF46E0404AB100000000088902FE.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1257_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1257_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/men1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/edm-ad/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1257_"><span class="title" itemprop="name">Multiple Endocrine Neoplasia Type 2</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: MEN 2, MEN 2 Syndrome</div><p class="contrib-group"><span itemprop="author">Charis Eng</span>, MD, PhD, FACP.</p><a data-jig="ncbitoggler" href="#__NBK1257_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1257_ai__"><div class="contrib half_rhythm"><span itemprop="author">Charis Eng</span>, MD, PhD, FACP<div class="affiliation small">Genomic Medicine Institute<br />Cleveland Clinic<br />Department of Genetics and Genome Sciences<br />Case Western Reserve University School of Medicine<br />Cleveland, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.fcc@cgne" class="oemail">gro.fcc@cgne</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">September 27, 1999</span>; Last Update: <span itemprop="dateModified">August 15, 2019</span>.</p><p><em>Estimated reading time: 43 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="men2.Summary" itemprop="description"><h2 id="_men2_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Multiple endocrine neoplasia type 2 (MEN 2) includes the following phenotypes: MEN 2A, FMTC (<a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> medullary thyroid carcinoma, which may be a variant of MEN 2A), and MEN 2B. All three phenotypes involve high risk for development of medullary carcinoma of the thyroid (MTC); MEN 2A and MEN 2B involve an increased risk for pheochromocytoma; MEN 2A involves an increased risk for parathyroid adenoma or hyperplasia. Additional features in MEN 2B include mucosal neuromas of the lips and tongue, distinctive facies with enlarged lips, ganglioneuromatosis of the gastrointestinal tract, and a marfanoid habitus. MTC typically occurs in early childhood in MEN 2B, early adulthood in MEN 2A, and middle age in FMTC.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of MEN 2 is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> who fulfills existing clinical diagnostic criteria. Molecular genetic testing to identify a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is indicated in all individuals with a diagnosis of primary C-cell hyperplasia or MTC or a clinical diagnosis of MEN 2. Identification of a heterozygous germline <i>RET</i> pathogenic variant on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> establishes the diagnosis if clinical features are inconclusive.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Treatment for MTC is surgical removal of the thyroid gland and lymph node dissection. External beam radiation therapy or intensity-modulated radiation therapy can be considered for advanced locoregional disease. Kinase inhibitors may be used in metastatic MTC. Pheochromocytomas detected by biochemical testing and radionuclide imaging are removed by adrenalectomy. Primary hyperparathyroidism is treated with surgery to remove one or more parathyroid glands, or more rarely, with medications to reduce parathyroid hormone secretion.</p><p><i>Prevention of primary manifestations:</i> Prophylactic thyroidectomy for individuals with an identified <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><i>Prevention of secondary complications:</i> Prior to any surgery in an individual with MEN 2A or MEN 2B, the presence of a functioning pheochromocytoma should be excluded by appropriate biochemical screening.</p><p><i>Surveillance:</i> Annual measurement of serum calcitonin concentration to detect residual or recurrent MTC after thyroidectomy, even if thyroidectomy was performed prior to biochemical evidence of disease. Monitoring for possible hypoparathyroidism in all those who have undergone thyroidectomy and parathyroid autotransplantation. Annual biochemical screening for those with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> whose initial screening results are negative for pheochromocytoma.</p><p><i>Agents/circumstances to avoid:</i> Dopamine D<sub>2</sub> receptor antagonists and &#x003b2;-adrenergic receptor antagonists present a high risk for adverse reactions in individuals with pheochromocytoma.</p><p><i>Evaluation of relatives at risk:</i>
<i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> should be offered to all at-risk members of kindreds in which a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified.</p><p><i>Pregnancy management</i>: Women with MEN 2 should be screened for pheochromocytoma prior to a planned pregnancy or as early as possible during an unplanned pregnancy.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>All MEN 2 phenotypes are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. The probability of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is 5% or less in index cases with MEN 2A and 50% in index cases with MEN 2B. Offspring of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have a 50% chance of inheriting the pathogenic variant. Prenatal testing for pregnancies at increased risk is possible if the <i>RET</i> pathogenic variant has been identified in an affected family member.</p></div></div><div id="men2.GeneReview_Scope"><h2 id="_men2_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="men2.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1257/table/men2.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__men2.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_men2.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Multiple Endocrine Neoplasia Type 2: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_men2.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>Multiple endocrine neoplasia type 2A (MEN 2A)</div></li><li class="half_rhythm"><div>Familial medullary thyroid carcinoma (FMTC)</div></li><li class="half_rhythm"><div>Multiple endocrine neoplasia type 2B (MEN 2B)</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#men2.Nomenclature">Nomenclature</a>.</p></div></dd><dt>1. </dt><dd><div id="men2.TF.c.1"><p class="no_margin">For other genetic causes of these phenotypes see <a href="#men2.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd></dl></div></div></div></div><div id="men2.Diagnosis"><h2 id="_men2_Diagnosis_">Diagnosis</h2><p>Clinical diagnostic criteria for multiple endocrine neoplasia type 2 (MEN 2) have been published [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>]; see <a href="#men2.Establishing_the_Diagnosis">Establishing the Diagnosis</a>.</p><div id="men2.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Multiple endocrine neoplasia type 2 (MEN 2) includes the phenotypes MEN 2A; <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> medullary thyroid carcinoma (FMTC), which may itself be a variant of MEN 2A; and MEN 2B.</p><p>MEN 2A <b>should be suspected</b> in individuals with one or more specific endocrine tumors: medullary thyroid carcinoma (MTC), pheochromocytoma, or parathyroid adenoma/hyperplasia.</p><p>FMTC <b>should be suspected</b> in families with more than one individual diagnosed with MTC in the absence of pheochromocytoma or parathyroid adenoma/hyperplasia.</p><p>MEN 2B <b>should be suspected</b> in individuals with distinctive facies including lip mucosal neuromas resulting in thick vermilion of the upper and lower lip, mucosal neuromas of the lips and tongue, medullated corneal nerve fibers, marfanoid habitus, and MTC.</p></div><div id="men2.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of MEN 2 <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the following clinical criteria. Identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1257/table/men2.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figmen2Tmoleculargenetictestingusedin" rid-ob="figobmen2Tmoleculargenetictestingusedin">Table 1</a>) establishes the diagnosis if clinical features are inconclusive.</p><p><b>Clinical criteria,</b> as outlined by <a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al [2009]</a>:</p><ul><li class="half_rhythm"><div><b>MEN 2A</b> is diagnosed clinically by the occurrence of two or more specific endocrine tumors (medullary thyroid carcinoma [MTC], pheochromocytoma, or parathyroid adenoma/hyperplasia) in a single individual or in close relatives.</div></li><li class="half_rhythm"><div><b>FMTC</b> is diagnosed in families with four or more cases of MTC in the absence of pheochromocytoma or parathyroid adenoma/hyperplasia.</div></li><li class="half_rhythm"><div><b>MEN 2B</b> is diagnosed clinically by the presence of early-onset MTC, mucosal neuromas of the lips and tongue, as well as medullated corneal nerve fibers, distinctive facies with enlarged lips, and an asthenic, marfanoid body habitus.</div></li></ul><p>When the phenotypic and laboratory findings suggest the diagnosis of MEN 2, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>.</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>RET</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Select-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> testing.</b> The majority of pathogenic variants occur in exons 10, 11, and 13-16 (<a class="figpopup" href="/books/NBK1257/table/men2.T.risk_for_aggressive_mtc_based_on/?report=objectonly" target="object" rid-figpopup="figmen2Triskforaggressivemtcbasedon" rid-ob="figobmen2Triskforaggressivemtcbasedon">Table 3</a>). Sequence analysis of select exons and <a class="def" href="/books/n/gene/glossary/def-item/targeted-analysis-for-pathogenic-variants/">targeted analysis for pathogenic variants</a> may be offered by some laboratories.</div><div class="half_rhythm">If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found by select-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> testing, full-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> sequencing of <i>RET</i> as part of a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> should be considered next.</div><div class="half_rhythm">Note: Since MEN 2 occurs through a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> mechanism and large intragenic <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> or <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> has not been reported, testing for intragenic deletions or duplications is not indicated.</div></li></ul><p><b>A cancer predisposition</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>RET</i> and other genes of interest (see <a href="#men2.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><div id="men2.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in MEN 2</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1257/table/men2.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__men2.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Method&#x000a0;<sup>2</sup></th><th id="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>3</sup> Detectable by Method</th></tr><tr><th headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">MEN 2A</th><th headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">FMTC</th><th headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MEN 2B</th></tr></thead><tbody><tr><td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>RET</i></td><td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>4,&#x000a0;5</sup></td><td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;98%&#x000a0;<sup>6,&#x000a0;7</sup></td><td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;95%&#x000a0;<sup>6,&#x000a0;8</sup></td><td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;98%&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis of select exons</td><td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">98%&#x000a0;<sup>6,&#x000a0;10</sup></td><td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">95%&#x000a0;<sup>6,&#x000a0;8</sup></td><td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants&#x000a0;<sup>11</sup></td><td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_men2.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_men2.T.molecular_genetic_testing_used_in_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">98%&#x000a0;<sup>9</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="men2.TF.1.1"><p class="no_margin">See <a href="/books/NBK1257/#men2.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="men2.TF.1.2"><p class="no_margin">Since MEN 2 occurs through a <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> mechanism, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> (such as <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification [MLPA], and gene-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications to detect intragenic deletions or duplications) is not indicated.</p></div></dd><dt>3. </dt><dd><div id="men2.TF.1.3"><p class="no_margin">See <a href="#men2.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>4. </dt><dd><div id="men2.TF.1.4"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>5. </dt><dd><div id="men2.TF.1.5"><p class="no_margin">Sequence analysis of all <i>RET</i> exons may be performed instead of sequencing of select exons. If sequencing of select exons has been previously performed with no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> detected, a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> including <i>RET</i> is recommended (see <a href="#men2.Establishing_the_Diagnosis">Establishing the Diagnosis</a>).</p></div></dd><dt>6. </dt><dd><div id="men2.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#men2.REF.hansford.2000.817">Hansford &#x00026; Mulligan [2000]</a>, <a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al [2009]</a></p></div></dd><dt>7. </dt><dd><div id="men2.TF.1.7"><p class="no_margin"><a class="bk_pop" href="#men2.REF.zbuk.2007.35">Zbuk &#x00026; Eng [2007]</a></p></div></dd><dt>8. </dt><dd><div id="men2.TF.1.8"><p class="no_margin">Pathogenic variants of codons 618, 620, and 634 each account for 20% to 30% of pathogenic variants. Other pathogenic variants in exons 5, 8, 10, 11, and 13-16 appear to account for a small percentage of pathogenic variants in families with FMTC, with an important minority affecting codons 768 and 804.</p></div></dd><dt>9. </dt><dd><div id="men2.TF.1.9"><p class="no_margin">Approximately 95% of individuals have a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> at codon 918 in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 16 [<a class="bk_pop" href="#men2.REF.eng.1996.1575">Eng et al 1996</a>]. A pathogenic variant in exon 15 has been identified in several <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#men2.REF.gimm.1997.3902">Gimm et al 1997</a>, <a class="bk_pop" href="#men2.REF.smith.1997.1213">Smith et al 1997</a>].</p></div></dd><dt>10. </dt><dd><div id="men2.TF.1.10"><p class="no_margin">Pathogenic variants in exons 10 and 11 [<a class="bk_pop" href="#men2.REF.eng.1996.1575">Eng et al 1996</a>, <a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>]</p></div></dd><dt>11. </dt><dd><div id="men2.TF.1.11"><p class="no_margin">Pathogenic variants typically detected: <a class="figpopup" href="/books/NBK1257/table/men2.T.ret_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmen2Tretpathogenicvariantsdiscussed" rid-ob="figobmen2Tretpathogenicvariantsdiscussed">p.Met918Thr</a>, <a class="figpopup" href="/books/NBK1257/table/men2.T.ret_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmen2Tretpathogenicvariantsdiscussed" rid-ob="figobmen2Tretpathogenicvariantsdiscussed">p.Ala883Phe</a>. Note: Pathogenic variants included in a panel may vary by laboratory.</p></div></dd></dl></div></div></div></div></div><div id="men2.Clinical_Characteristics"><h2 id="_men2_Clinical_Characteristics_">Clinical Characteristics</h2><div id="men2.Clinical_Description"><h3>Clinical Description</h3><p>The endocrine disorders observed in multiple endocrine neoplasia type 2 (MEN 2) are: <a href="#men2.MTC_and_CCH">medullary thyroid carcinoma</a> (MTC) and/or its precursor, C-cell hyperplasia (CCH); <a href="#men2.Pheochromocytoma">pheochromocytoma</a>; and <a href="#men2.Parathyroid_Abnormalities">parathyroid adenoma or hyperplasia</a>.</p><div id="men2.MTC_and_CCH"><h4>MTC and CCH</h4><p><b>Clinical findings.</b> MTC in persons with MEN 2 typically presents at a younger age than <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> MTC and is more often associated with C-cell hyperplasia as well as multifocality or bilaterality.</p><ul><li class="half_rhythm"><div>Symptoms of MTC include neck mass or neck pain prior to age 35 years. Diarrhea (the most frequent systemic symptom) occurs in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with a plasma calcitonin concentration &#x0003e;10 ng/mL and implies a poor prognosis [<a class="bk_pop" href="#men2.REF.callender.2008.863">Callender et al 2008</a>].</div></li><li class="half_rhythm"><div>Up to 70% of individuals with a palpable thyroid mass or diarrhea already have cervical lymph node metastases [<a class="bk_pop" href="#men2.REF.cohen.2003.616">Cohen &#x00026; Moley 2003</a>]. Metastatic spread to regional lymph nodes (i.e., parathyroid, paratracheal, jugular chain, and upper mediastinum) or to distant sites including the liver, lungs, or bone is also common in symptomatic individuals [<a class="bk_pop" href="#men2.REF.moley.1998.521">Moley et al 1998</a>, <a class="bk_pop" href="#men2.REF.cohen.2003.616">Cohen &#x00026; Moley 2003</a>].</div></li><li class="half_rhythm"><div>About 25%-30% of all individuals with MTC have a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. In a large series of individuals with <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> medullary thyroid carcinoma (i.e., no known family history of MTC or personal history of other endocrine disease), approximately 7% had a germline <i>RET</i> pathogenic variant [<a class="bk_pop" href="#men2.REF.elisei.2007.4725">Elisei et al 2007</a>].</div></li></ul><p><b>Biochemical findings.</b> MTC and CCH are suspected in the presence of an elevated plasma calcitonin concentration, a sensitive and specific marker. In provocative testing, plasma calcitonin concentration is measured before (basal level), then two and five minutes after intravenous administration of calcium (stimulated level). Other calcitonin secretagogues such as pentagastrin (available in Europe, limited in the US) are also used. A basal or stimulated calcitonin level of &#x02265;100 pg/mL is an indication for surgery [<a class="bk_pop" href="#men2.REF.costante.2007.450">Costante et al 2007</a>, <a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</p><p>Note: All individuals with an MTC-predisposing <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> who have not undergone prophylactic thyroidectomy demonstrate biochemical evidence of MTC by age 35 years [<a class="bk_pop" href="#men2.REF.delellis.2004">DeLellis et al 2004</a>].</p><p><b>Histology.</b> MTC originates in calcitonin-producing cells (C cells) of the thyroid gland. MTC is diagnosed histologically when nests of C cells appear to extend beyond the basement membrane and to infiltrate and destroy thyroid follicles. Immunohistochemistry for calcitonin expression may be performed as a pathologic diagnostic adjunct.</p><p>CCH is diagnosed histologically by the presence of an increased number of diffusely scattered or clustered C cells. In MEN 2, the age of transformation from CCH to MTC varies with different <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> RET pathogenic variants [<a class="bk_pop" href="#men2.REF.machens.2003.1517">Machens et al 2003</a>].</p></div><div id="men2.Pheochromocytoma"><h4>Pheochromocytoma</h4><p><b>Clinical findings.</b> Pheochromocytomas in individuals with MEN 2 are nearly always adrenal and often bilateral [<a class="bk_pop" href="#men2.REF.pomares.1998.195">Pomares et al 1998</a>, <a class="bk_pop" href="#men2.REF.pacak.2005.60">Pacak et al 2005</a>, <a class="bk_pop" href="#men2.REF.thosani.2013.e1813">Thosani et al 2013</a>].</p><ul><li class="half_rhythm"><div>Individuals with a confirmed <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> who present with head and neck paraganglioma all have a personal and/or family history consistent with MEN 2 [<a class="bk_pop" href="#men2.REF.boedeker.2009.1938">Boedeker et al 2009</a>].</div></li><li class="half_rhythm"><div>Although pheochromocytomas in individuals with MEN 2 rarely metastasize, they can be lethal because of intractable hypertension or anesthesia-induced hypertensive crises.</div></li></ul><p><b>Biochemical findings.</b> Pheochromocytoma is suspected when biochemical screening reveals elevated excretion of catecholamines and catecholamine metabolites (e.g., norepinephrine, epinephrine, metanephrine, and vanillylmandelic acid [VMA]) in plasma or 24-hour urine collections [<a class="bk_pop" href="#men2.REF.pacak.2005.60">Pacak et al 2005</a>, <a class="bk_pop" href="#men2.REF.ilias.2009.89">Ilias &#x00026; Pacak 2009</a>]. In MEN 2, pheochromocytomas consistently produce epinephrine or epinephrine and norepinephrine [<a class="bk_pop" href="#men2.REF.ilias.2009.89">Ilias &#x00026; Pacak 2009</a>].</p><p><b>Imaging.</b> Abdominal MRI and/or CT is performed if plasma or urinary catecholamine values are increased or if a pheochromocytoma is suspected clinically. MRI is more sensitive than CT in detection of a pheochromocytoma.</p><p>[<sup>18</sup>F]-fluorodopamine ([<sup>18</sup>F]DA) PET is the best overall imaging modality in the localization of pheochromocytomas. If [<sup>18</sup>F]DA PET is unavailable, MIBG (<sup>123</sup>I- or <sup>131</sup>I-labeled metaiodobenzylguanidine) scintigraphy should be used to further evaluate individuals with biochemical or radiographic evidence of pheochromocytoma [<a class="bk_pop" href="#men2.REF.ilias.2008.1613">Ilias et al 2008</a>]. <sup>68</sup>Ga-DOTATATE-PET-CT results correlate best with biochemical parameters (reviewed in <a class="bk_pop" href="#men2.REF.neumann.2019.552">Neumann et al [2019]</a>).</p></div><div id="men2.Parathyroid_Abnormalities"><h4>Parathyroid Abnormalities</h4><p><b>Clinical findings.</b> Parathyroid abnormalities can range from benign parathyroid adenomas to clinically evident hyperparathyroidism with hypercalcemia and renal stones.</p><p><b>Biochemical findings.</b> Parathyroid abnormalities are present when elevated serum calcium occurs simultaneously with elevated or high-normal parathyroid hormone (PTH).</p><p><b>Imaging.</b> Postoperative parathyroid localizing studies with <sup>99m</sup>Tc-sestamibi scintigraphy may be helpful if hyperparathyroidism recurs. For preoperative adenoma localization, three-dimensional single-photon emission CT (SPECT) may also be used [<a class="bk_pop" href="#men2.REF.brenner.2008.1117">Brenner &#x00026; Jacene 2008</a>].</p></div><div id="men2.MEN_2_Phenotypes"><h4>MEN 2 Phenotypes</h4><p>MEN 2 is classified into three phenotypes: MEN 2A, FMTC (which is now considered a variant of MEN 2A), and MEN 2B (<a class="figpopup" href="/books/NBK1257/table/men2.T.percent_of_clinical_features_by_m/?report=objectonly" target="object" rid-figpopup="figmen2Tpercentofclinicalfeaturesbym" rid-ob="figobmen2Tpercentofclinicalfeaturesbym">Table 2</a>). All three phenotypes involve high risk for MTC; individuals with MEN 2A and MEN 2B are at increased risk for pheochromocytoma; individuals with MEN 2A are at increased risk for parathyroid hyperplasia or adenoma. Classifying an individual or family by MEN 2 <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is useful for determining prognosis and management.</p><div id="men2.T.percent_of_clinical_features_by_m" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Percent of Clinical Features by MEN 2 Phenotype</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1257/table/men2.T.percent_of_clinical_features_by_m/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__men2.T.percent_of_clinical_features_by_m_lrgtbl__"><table><thead><tr><th id="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Medullary Thyroid Carcinoma</th><th id="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pheochromocytoma</th><th id="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Parathyroid Disease</th></tr></thead><tbody><tr><td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>MEN 2A</b></td><td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">95%</td><td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</td><td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%-30%</td></tr><tr><td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>FMTC</b></td><td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%</td><td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0%</td></tr><tr><td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>MEN 2B</b></td><td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td><td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</td><td headers="hd_h_men2.T.percent_of_clinical_features_by_m_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Uncommon</td></tr></tbody></table></div></div><p><b>MEN 2A.</b> The MEN 2A <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> constitutes approximately 70%-80% of cases of MEN 2. MTC is generally the first manifestation of MEN 2A. Since genetic testing for <i>RET</i> pathogenic variants has become available, it has become apparent that 95% of individuals with MEN 2A develop MTC, about 50% develop pheochromocytoma, and about 20%-30% develop hyperparathyroidism (reviewed by <a class="bk_pop" href="#men2.REF.neumann.2019.552">Neumann et al [2019]</a>).</p><p>Pheochromocytomas usually present after MTC or concomitantly; however, they are the first sign in 13%-27% of individuals with MEN 2A [<a class="bk_pop" href="#men2.REF.inabnet.2000.1007">Inabnet et al 2000</a>, <a class="bk_pop" href="#men2.REF.rodriguez.2008.2520">Rodriguez et al 2008</a>]. Pheochromocytomas in persons with MEN 2A are diagnosed at an earlier age, have subtler symptoms, and are more likely to be bilateral than <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> tumors [<a class="bk_pop" href="#men2.REF.pomares.1998.195">Pomares et al 1998</a>, <a class="bk_pop" href="#men2.REF.pacak.2005.60">Pacak et al 2005</a>]. Malignant transformation occurs in about 4% of cases [<a class="bk_pop" href="#men2.REF.modigliani.1995.363">Modigliani et al 1995</a>]. Since pheochromocytoma can be the first manifestation of MEN 2A, the diagnosis of pheochromocytoma in an individual warrants further investigation for MEN 2A [<a class="bk_pop" href="#men2.REF.neumann.2019.552">Neumann et al 2019</a>].</p><p>Hyperparathyroidism (HPT) in MEN 2A is typically mild and may range from a single adenoma to marked hyperplasia. Most individuals with hyperparathyroidism have no symptoms; however, hypercalciuria and renal calculi may occur [<a class="bk_pop" href="#men2.REF.brandi.2001.5658">Brandi et al 2001</a>]. HPT usually presents many years after the diagnosis of MTC; the average age at onset is 38 years [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</p><p>A small number of families with MEN 2A have pruritic cutaneous lichen amyloidosis, also known as cutaneous lichen amyloidosis. This lichenoid skin lesion is located over the upper portion of the back and may appear before the onset of MTC [<a class="bk_pop" href="#men2.REF.seri.1997.86">Seri et al 1997</a>].</p><p><b>FMTC.</b> The FMTC <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> constitutes approximately 10%-20% of cases of MEN 2. By operational definition, MTC is the only clinical manifestation of FMTC. Currently, FMTC is viewed as a variant of MEN 2A with decreased <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of pheochromocytoma and hyperparathyroidism, rather than a distinct subtype [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</p><p>The age of onset of MTC is later in FMTC and the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of MTC is lower than that observed in MEN 2A and MEN 2B [<a class="bk_pop" href="#men2.REF.eng.1996.1575">Eng et al 1996</a>, <a class="bk_pop" href="#men2.REF.machens.2001.1104">Machens et al 2001</a>, <a class="bk_pop" href="#men2.REF.machens.2006.34">Machens &#x00026; Dralle 2006</a>, <a class="bk_pop" href="#men2.REF.zbuk.2007.35">Zbuk &#x00026; Eng 2007</a>, <a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>]. To avoid erroneously dismissing a risk for pheochromocytoma, strict criteria should be met before a family is classified as having FMTC (see <a href="#men2.Establishing_the_Diagnosis">Establishing the Diagnosis</a>, <b>Clinical criteria</b>).</p><p><b>MEN 2B.</b> The MEN 2B <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> accounts for approximately 5% of cases of MEN 2. MEN 2B is characterized by the early development of an aggressive form of MTC in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#men2.REF.skinner.1996.177">Skinner et al 1996</a>]. Individuals with MEN 2B who do not undergo thyroidectomy before age one year are likely to develop metastatic MTC at an early age. Prior to intervention with early prophylactic thyroidectomy, the median age of death in individuals with MEN 2B was 25 years (range: 0.5-66) [<a class="bk_pop" href="#men2.REF.castinetti.2019.213">Castinetti et al 2019</a>].</p><p>Pheochromocytomas occur in 50% of individuals with MEN 2B; about half are multiple and often bilateral. Individuals with an undiagnosed pheochromocytoma may die from a cardiovascular hypertensive crisis perioperatively.</p><p>Clinically significant parathyroid disease is absent in MEN 2B.</p><p>Individuals with MEN 2B may be identified in infancy or early childhood by a distinctive facial appearance and the presence of mucosal neuromas on the anterior dorsal surface of the tongue, palate, or pharynx. The lips become prominent (or "blubbery") over time, and submucosal nodules may be present on the vermilion border of the lips. Neuromas of the eyelids may cause thickening and eversion of the upper eyelid margins. Prominent thickened corneal nerves may be seen by slit lamp examination.</p><p>About 40% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have diffuse ganglioneuromatosis of the gastrointestinal tract. Associated symptoms include abdominal distension, megacolon, constipation, or diarrhea. In one study of 19 individuals with MEN 2B, 84% reported gastrointestinal symptoms beginning in infancy or early childhood [<a class="bk_pop" href="#men2.REF.wray.2008.293">Wray et al 2008</a>].</p><p>About 75% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have a marfanoid habitus, often with kyphoscoliosis or lordosis, joint laxity, and decreased subcutaneous fat. Proximal muscle wasting and weakness can also be seen.</p></div></div><div id="men2.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Pathogenic variants involving the cysteine codons 609, 618, and 620 in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 10 of <i>RET</i> are associated with MEN 2A, FMTC, and HSCR1 [<a class="bk_pop" href="#men2.REF.mulligan.1994.2163">Mulligan et al 1994</a>, <a class="bk_pop" href="#men2.REF.decker.1998.129">Decker et al 1998</a>, <a class="bk_pop" href="#men2.REF.romeo.1998.515">Romeo et al 1998</a>, <a class="bk_pop" href="#men2.REF.inoue.1999.1552">Inoue et al 1999</a>, <a class="bk_pop" href="#men2.REF.takahashi.1999.331">Takahashi et al 1999</a>]. A <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of these codons is detected in about 10% of families with MEN 2A and more than 50% of families with FMTC; these pathogenic variants are associated with low transforming activity of <i>RET</i> [<a class="bk_pop" href="#men2.REF.takahashi.1998.509">Takahashi et al 1998</a>, <a class="bk_pop" href="#men2.REF.hansford.2000.817">Hansford &#x00026; Mulligan 2000</a>].</p><p><i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1257/table/men2.T.ret_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmen2Tretpathogenicvariantsdiscussed" rid-ob="figobmen2Tretpathogenicvariantsdiscussed">p.Met918Thr</a> is only associated with MEN 2B; however, somatic pathogenic variants at this codon are frequently observed in MTC in individuals with no known family history of MTC, and are overrepresented in individuals with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> MTC who have the <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/germline-variant/">germline variant</a> <a class="figpopup" href="/books/NBK1257/table/men2.T.putative_ret_benignmodifierpredis/?report=objectonly" target="object" rid-figpopup="figmen2Tputativeretbenignmodifierpredis" rid-ob="figobmen2Tputativeretbenignmodifierpredis">p.Ser836</a> [<a class="bk_pop" href="#men2.REF.gimm.1999.1369">Gimm et al 1999</a>].</p><p>Any <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> at codon 634 in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 11 results in a higher incidence of pheochromocytomas and hyperparathyroidism [<a class="bk_pop" href="#men2.REF.eng.1996.1575">Eng et al 1996</a>, <a class="bk_pop" href="#men2.REF.yip.2003.409">Yip et al 2003</a>, <a class="bk_pop" href="#men2.REF.zbuk.2007.35">Zbuk &#x00026; Eng 2007</a>, <a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</p><ul><li class="half_rhythm"><div>A report of 12 Brazilian families indicated that <a class="figpopup" href="/books/NBK1257/table/men2.T.ret_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmen2Tretpathogenicvariantsdiscussed" rid-ob="figobmen2Tretpathogenicvariantsdiscussed">p.Cys634Arg</a> is associated with a higher probability of having metastases at diagnosis than other codon 634 pathogenic variants [<a class="bk_pop" href="#men2.REF.pu_ales.2003.2644">Pu&#x000f1;ales et al 2003</a>].</div></li><li class="half_rhythm"><div>Codon 634 pathogenic variants are also associated with development of cutaneous lichen amyloidosis [<a class="bk_pop" href="#men2.REF.seri.1997.86">Seri et al 1997</a>]. Among 25 individuals from three families with a codon 634 <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, 36% had cutaneous lichen amyloidosis [<a class="bk_pop" href="#men2.REF.verga.2003.156">Verga et al 2003</a>].</div></li><li class="half_rhythm"><div>While 25% of FMTC kindreds harbor a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in codon 634, <a class="figpopup" href="/books/NBK1257/table/men2.T.ret_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmen2Tretpathogenicvariantsdiscussed" rid-ob="figobmen2Tretpathogenicvariantsdiscussed">p.Cys634Arg</a> pathogenic variants are virtually absent in this subtype [<a class="bk_pop" href="#men2.REF.hansford.2000.817">Hansford &#x00026; Mulligan 2000</a>, <a class="bk_pop" href="#men2.REF.zbuk.2007.35">Zbuk &#x00026; Eng 2007</a>].</div></li></ul><p>Pathogenic variants at codons 768, 804, and 891 that were initially only associated with MTC have subsequently been found in families with MEN 2A [<a class="bk_pop" href="#men2.REF.jimenez.2004a.3521">Jimenez et al 2004a</a>, <a class="bk_pop" href="#men2.REF.aiello.2005.574">Aiello et al 2005</a>, <a class="bk_pop" href="#men2.REF.schulte.2010.e92">Schulte et al 2010</a>].</p><ul><li class="half_rhythm"><div>Initially thought to be associated with MTC only, pathogenic variants at codon 804 in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 14 (e.g., <a class="figpopup" href="/books/NBK1257/table/men2.T.ret_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmen2Tretpathogenicvariantsdiscussed" rid-ob="figobmen2Tretpathogenicvariantsdiscussed">p.Val804Leu</a> and <a class="figpopup" href="/books/NBK1257/table/men2.T.ret_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmen2Tretpathogenicvariantsdiscussed" rid-ob="figobmen2Tretpathogenicvariantsdiscussed">p.Val804Met</a>) were subsequently identified in individuals with pheochromocytoma [<a class="bk_pop" href="#men2.REF.nilsson.1999.1587">Nilsson et al 1999</a>, <a class="bk_pop" href="#men2.REF.h_ie.2000.3249">H&#x000f8;ie et al 2000</a>, <a class="bk_pop" href="#men2.REF.gibelin.2004.1458">Gibelin et al 2004</a>, <a class="bk_pop" href="#men2.REF.jimenez.2004a.3521">Jimenez et al 2004a</a>].</div></li><li class="half_rhythm"><div>Disease expression of pathogenic variants at codon 804 has been shown to be highly variable, even within the same family [<a class="bk_pop" href="#men2.REF.feldman.2000.93">Feldman et al 2000</a>, <a class="bk_pop" href="#men2.REF.frohnauer.2000.1052">Frohnauer &#x00026; Decker 2000</a>]. Some individuals with such pathogenic variants have had MTC at age five years and fatal metastatic MTC at age 12 years, whereas other individuals with the same <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have been shown to have normal thyroid histology at age 27 years, normal biochemical screening at age 40 years, and no clinical evidence of MTC at age 86 years.</div></li><li class="half_rhythm"><div>In another large family with a high level of <a class="def" href="/books/n/gene/glossary/def-item/consanguinity/">consanguinity</a>, biochemical testing indicated expression of thyroid disease in individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> but not <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for p.Val804Met [<a class="bk_pop" href="#men2.REF.lecube.2002.509">Lecube et al 2002</a>].</div></li><li class="half_rhythm"><div>Cutaneous lichen amyloidosis in association with a p.Val804Met <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been reported in one individual [<a class="bk_pop" href="#men2.REF.rothberg.2009.651">Rothberg et al 2009</a>].</div></li></ul><p>One study suggests that in addition to their association with MTC, pathogenic variants in codons 790 or 804 may be associated with papillary thyroid carcinoma [<a class="bk_pop" href="#men2.REF.brauckhoff.2002.557">Brauckhoff et al 2002</a>]. In a large Italian family, 40% of family members with a p.Val804Met <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> who were examined in detail had concomitant medullary and papillary thyroid carcinoma [<a class="bk_pop" href="#men2.REF.shifrin.2009.998">Shifrin et al 2009</a>].</p><p>The American Thyroid Association Guidelines Task Force has classified pathogenic variants based on their risk for aggressive MTC [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>]. The classification may be used in (1) predicting <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and in (2) recommendations regarding the ages at which to (a) perform prophylactic thyroidectomy and (b) begin biochemical screening for pheochromocytoma and hyperparathyroidism (see <a class="figpopup" href="/books/NBK1257/table/men2.T.risk_for_aggressive_mtc_based_on/?report=objectonly" target="object" rid-figpopup="figmen2Triskforaggressivemtcbasedon" rid-ob="figobmen2Triskforaggressivemtcbasedon">Table 3</a> and <a href="#men2.Surveillance">Surveillance</a>).</p></div><div id="men2.Penetrance"><h3>Penetrance</h3><p>The <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> for MTC, pheochromocytoma, and parathyroid disease varies by MEN 2 <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (see <a class="figpopup" href="/books/NBK1257/table/men2.T.percent_of_clinical_features_by_m/?report=objectonly" target="object" rid-figpopup="figmen2Tpercentofclinicalfeaturesbym" rid-ob="figobmen2Tpercentofclinicalfeaturesbym">Table 2</a>).</p></div><div id="men2.Nomenclature"><h3>Nomenclature</h3><p>MEN 2A is also referred to as Sipple syndrome.</p><p>Mucosal neuroma syndrome is a synonym for MEN 2B. MEN 2B was initially called Wagenmann-Froboese syndrome [<a class="bk_pop" href="#men2.REF.morrison.1996.779">Morrison &#x00026; Nevin 1996</a>].</p></div><div id="men2.Prevalence"><h3>Prevalence</h3><p>The prevalence of MEN 2 has been estimated at 1:35,000 [<a class="bk_pop" href="#men2.REF.delellis.2004">DeLellis et al 2004</a>].</p></div></div><div id="men2.Genetically_Related_Allelic_Disorde"><h2 id="_men2_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p><a href="/books/n/gene/hirschsprung-ov/"><b>Hirschsprung disease</b></a>
<b>(HSCR).</b> Germline <i>RET</i> pathogenic variants are associated with HSCR, a disorder of the enteric plexus of the colon that typically results in enlargement of the bowel and constipation or obstipation in neonates. About 50% of <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cases and 35% of <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single occurrence in a family) of HSCR are caused by a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the <i>RET</i> proto-oncogene [<a class="bk_pop" href="#men2.REF.kouvaraki.2005.531">Kouvaraki et al 2005</a>] (see <a href="#men2.Molecular_Genetics">Molecular Genetics</a>, <b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a></b>).Germline pathogenic variants causing HSCR occur throughout the coding sequence of <i>RET</i> [<a class="bk_pop" href="#men2.REF.takahashi.1999.331">Takahashi et al 1999</a>]. Families and individuals with a germline <i>RET</i> pathogenic variant in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 10, especially affecting codons 618 and 620, often cosegregate MEN 2A/FMTC and HSCR [<a class="bk_pop" href="#men2.REF.eng.1996.1575">Eng et al 1996</a>, <a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</p></div><div id="men2.Differential_Diagnosis"><h2 id="_men2_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>MTC in individuals with no family history of MTC.</b> Medullary thyroid carcinoma accounts for approximately 10% of new cases of thyroid cancer diagnosed annually in the US. Sporadic MTC tends to be unifocal, have a later age of onset, and lack C-cell hyperplasia (CCH) [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</p><p>DNA analysis of MTC tissue revealed a 40%-50% incidence of somatic <i>RET</i> variants in the <i>absence</i> of a <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#men2.REF.schilling.2001.62">Schilling et al 2001</a>, <a class="bk_pop" href="#men2.REF.de_groot.2006.535">de Groot et al 2006</a>, <a class="bk_pop" href="#men2.REF.dvorakova.2008.21">Dvorakova et al 2008</a>, <a class="bk_pop" href="#men2.REF.elisei.2008.682">Elisei et al 2008</a>]. The somatic <a class="figpopup" href="/books/NBK1257/table/men2.T.ret_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmen2Tretpathogenicvariantsdiscussed" rid-ob="figobmen2Tretpathogenicvariantsdiscussed">p.Met918Thr</a> variant is the most common; variants at other codons as well as small <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletions have been reported [<a class="bk_pop" href="#men2.REF.de_groot.2006.535">de Groot et al 2006</a>]. Tumors with a somatic codon 918 variant appear to be more aggressive [<a class="bk_pop" href="#men2.REF.schilling.2001.62">Schilling et al 2001</a>, <a class="bk_pop" href="#men2.REF.elisei.2008.682">Elisei et al 2008</a>].</p><p><b>C-cell hyperplasia (CCH).</b> CCH associated with a positive calcitonin stimulation test occurs in about 5% of the general population. Serum calcitonin levels may be elevated in persons with chronic renal failure, sepsis, neuroendocrine tumors of the lung or gastrointestinal tract, hypergastrinemia, mastocytosis, autoimmune thyroid disease, and type 1A pseudohypoparathyroidism [<a class="bk_pop" href="#men2.REF.costante.2009.35">Costante et al 2009</a>].</p><p>Secondary CCH has been described occasionally in the setting of aging and hyperparathyroidism. Secondary CCH rarely transforms to MTC and is not related to MEN 2.</p><p><b>Pheochromocytoma.</b> Up to 25% of individuals with pheochromocytoma and no known family history of pheochromocytoma have a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of several genes: <i>RET</i>, <i>VHL</i>, <i>SDHD</i>, or <i>SDHB</i> [<a class="bk_pop" href="#men2.REF.neumann.2002.1459">Neumann et al 2002</a>, <a class="bk_pop" href="#men2.REF.bryant.2003.1196">Bryant et al 2003</a>, <a class="bk_pop" href="#men2.REF.neumann.2004.943">Neumann et al 2004</a>]. Approximately 5% of individuals with nonsyndromic pheochromocytoma and no family history of pheochromocytoma were heterozygous for a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RET</i> pathogenic variant [<a class="bk_pop" href="#men2.REF.neumann.2002.1459">Neumann et al 2002</a>]. Other pheochromocytoma susceptibility genes including <i>SDHC</i>, <i>TMEM127</i>, <i>MAX</i>, and <i>SDHA</i> further expand the differential diagnosis for nonsyndromic paraganglioma and pheochromocytoma [<a class="bk_pop" href="#men2.REF.peczkowska.2008.111">Peczkowska et al 2008</a>, <a class="bk_pop" href="#men2.REF.burnichon.2009.2817">Burnichon et al 2009</a>, <a class="bk_pop" href="#men2.REF.bayley.2010.366">Bayley et al 2010</a>, <a class="bk_pop" href="#men2.REF.burnichon.2010.3011">Burnichon et al 2010</a>, <a class="bk_pop" href="#men2.REF.qin.2010.229">Qin et al 2010</a>, <a class="bk_pop" href="#men2.REF.cominom_ndez.2011.663">Comino-M&#x000e9;ndez et al 2011</a>, <a class="bk_pop" href="#men2.REF.vandy.2011.805">Vandy et al 2011</a>]. An algorithm for prioritizing which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) to test is outlined by <a class="bk_pop" href="#men2.REF.erlic.2009.6378">Erlic et al [2009]</a>, <a class="bk_pop" href="#men2.REF.neumann.2009.3650">Neumann et al [2009]</a>, and <a class="bk_pop" href="#men2.REF.welander.2011.r253">Welander et al [2011]</a>. However, multigene panels may also be considered for individuals with no <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> features.</p><p>Evaluation of biochemical features can help differentiate MEN 2-associated pheochromocytoma. <a class="bk_pop" href="#men2.REF.pacak.2005.60">Pacak et al [2005]</a> compared biochemical profiles for inherited and <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> pheochromocytoma and found that MEN 2 can be ruled out in pheochromocytomas that exclusively produce normetanephrine.</p><ul><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/vhl/"><b>von Hippel-Lindau (VHL) syndrome</b></a><b>.</b> Any individual presenting with a pheochromocytoma should be evaluated for VHL syndrome [<a class="bk_pop" href="#men2.REF.erlic.2009.6378">Erlic et al 2009</a>]. VHL syndrome is characterized by pheochromocytoma, renal cell carcinoma, cerebellar and spinal hemangioblastoma, and retinal angioma.</div><div class="half_rhythm">Some families with apparent <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> pheochromocytoma have a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>VHL</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the absence of other clinical manifestations of VHL syndrome [<a class="bk_pop" href="#men2.REF.inabnet.2000.1007">Inabnet et al 2000</a>]. <a class="bk_pop" href="#men2.REF.neumann.2002.1459">Neumann et al [2002]</a> identified germline <i>VHL</i> pathogenic variants in 11% of individuals with nonsyndromic pheochromocytoma and no family history of pheochromocytoma. However, a US-based study found no pathogenic variants in <i>VHL</i> in individuals with nonsyndromic pheochromocytoma or paraganglioma [<a class="bk_pop" href="#men2.REF.fishbein.2013.1444">Fishbein et al 2013</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/paragangliomas/"><b>Hereditary paraganglioma-pheochromocytoma syndrome</b></a><b>.</b> Pathogenic variants in the succinate dehydrogenase genes <i>SDHA</i>, <i>SDHB</i>, <i>SDHC</i>, <i>SDHD</i>, and <i>SDHAF2</i> cause hereditary paraganglioma-pheochromocytoma syndrome. Early studies found that approximately 8.5% of individuals with apparently nonfamilial nonsyndromic pheochromocytoma have a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one of the genes (<i>SDHD</i> or <i>SDHB</i>) encoding the succinate dehydrogenase subunits that cause the hereditary paraganglioma-pheochromocytoma syndromes (reviewed in <a class="bk_pop" href="#men2.REF.neumann.2019.552">Neumann et al [2019]</a>). While head and neck paragangliomas are common in individuals with hereditary paraganglioma-pheochromocytoma syndrome, they are extremely rare in MEN 2 [<a class="bk_pop" href="#men2.REF.boedeker.2009.1938">Boedeker et al 2009</a>]. Although pathogenic variants in <i>SDHC</i> initially were thought to only cause head/neck paragangliomas, several cases of <i>SDHC-</i>associated pheochromocytoma have been reported in the literature [<a class="bk_pop" href="#men2.REF.peczkowska.2008.111">Peczkowska et al 2008</a>, <a class="bk_pop" href="#men2.REF.burnichon.2009.2817">Burnichon et al 2009</a>, <a class="bk_pop" href="#men2.REF.vandy.2011.805">Vandy et al 2011</a>]. <a class="bk_pop" href="#men2.REF.korpershoek.2011.e1472">Korpershoek et al [2011]</a> found an <i>SDHA</i> germline pathogenic variant in 3% of individuals with apparently <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> paragangliomas and pheochromocytomas. The <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <i>SDHAF2</i> is a rare cause of hereditary head/neck paraganglioma and is not associated with pheochromocytoma [<a class="bk_pop" href="#men2.REF.bayley.2010.366">Bayley et al 2010</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b><i>TMEM127-</i>associated susceptibility to pheochromocytoma</b> (OMIM <a href="http://omim.org/entry/613403" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613403</a>). Recent studies estimate that 1%-2% of individuals with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> or nonfamilial pheochromocytoma have a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>TMEM127</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#men2.REF.yao.2010.2611">Yao et al 2010</a>, <a class="bk_pop" href="#men2.REF.abermil.2012.e805">Abermil et al 2012</a>]. A few individuals with a germline <i>TMEM127</i> pathogenic variant have paragangliomas of the head/neck or at extra-adrenal sites [<a class="bk_pop" href="#men2.REF.neumann.2011.e1279">Neumann et al 2011</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b><i>MAX-</i>associated susceptibility to pheochromocytoma</b> (OMIM <a href="http://omim.org/entry/154950" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">154950</a>). A <i>MAX</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is seen in approximately 1% of individuals with <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> or nonfamilial pheochromocytoma [<a class="bk_pop" href="#men2.REF.burnichon.2012a.5397">Burnichon et al 2012a</a>]. Pheochromocytomas in individuals with <i>MAX</i> pathogenic variants are often bilateral [<a class="bk_pop" href="#men2.REF.burnichon.2012b.2828">Burnichon et al 2012b</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/nf1/"><b>Neurofibromatosis type 1</b></a>
<b>(NF1).</b> Pheochromocytomas are observed on occasion in NF1. Most individuals with NF1 can be diagnosed based on clinical features including multiple caf&#x000e9; au lait macules, neurofibromas, Lisch nodules, axillary or inguinal freckling, and/or positive family history.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Polycythemia and paraganglioma/pheochromocytoma.</b> Germline <i>DNMT3A</i>, <i>EGLN1</i>, <i>EGLN2</i>, <i>EPAS1</i>, <i>FH</i>, <i>HIF2A</i>, <i>IDH1</i>, <i>KIF1B</i>, <i>MDH2</i>, and <i>SLC25A11</i> pathogenic variants have been identified in individuals with polycythemia and paraganglioma [<a class="bk_pop" href="#men2.REF.lorenzo.2013.507">Lorenzo et al 2013</a>, <a class="bk_pop" href="#men2.REF.ta_eb.2013.e908">Ta&#x000ef;eb et al 2013</a>, <a class="bk_pop" href="#men2.REF.castrovega.2014.2440">Castro-Vega et al 2014</a>, <a class="bk_pop" href="#men2.REF.casc_n.2015.107">Casc&#x000f3;n et al 2015</a>, <a class="bk_pop" href="#men2.REF.yang.2015.93">Yang et al 2015</a>, <a class="bk_pop" href="#men2.REF.buffet.2018.1914">Buffet et al 2018</a>, <a class="bk_pop" href="#men2.REF.remacha.2018.1644">Remacha et al 2018</a>].</div></li></ul><p><a href="/books/n/gene/men1/"><b>Multiple endocrine neoplasia type 1</b></a>
<b>(MEN 1).</b> This endocrinopathy is genetically and clinically distinct from MEN 2; the similar nomenclature for MEN 1 and MEN 2 may cause confusion. MEN 1 is characterized by a triad of pituitary adenomas, pancreatic islet cell tumors, and parathyroid disease consisting of hyperplasia or adenoma. Affected individuals can also have adrenal cortical tumors, carcinoid tumors, and lipomas [<a class="bk_pop" href="#men2.REF.giraud.1998.455">Giraud et al 1998</a>]. MEN 1 is caused by a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>MEN1</i> and inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p><p><b>Multiple endocrine neoplasia type 4 (MEN 4).</b> While pheochromocytomas developed in the MENX rat model, humans with pathogenic variants in <i>CDKN1B</i> tend to have a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> similar to MEN 1, with a high incidence of pituitary tumors and primary hyperparathyroidism [<a class="bk_pop" href="#men2.REF.lee.2013.781">Lee &#x00026; Pellegata 2013</a>].</p></div><div id="men2.Management"><h2 id="_men2_Management_">Management</h2><div id="men2.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with multiple endocrine neoplasia type 2 (MEN 2), the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Referral to an endocrinologist</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li><li class="half_rhythm"><div>Biochemical evaluations:</div><ul><li class="half_rhythm"><div>Plasma calcitonin</div></li><li class="half_rhythm"><div>Plasma catecholamines and metanephrines</div></li><li class="half_rhythm"><div>Serum calcium and parathyroid hormone</div></li></ul></li><li class="half_rhythm"><div>Evaluation for metastatic disease in individuals with MTC</div><ul><li class="half_rhythm"><div>CT with contrast for chest and abdomen</div></li><li class="half_rhythm"><div>MRI of liver in the presence of nodal disease or calcitonin &#x0003e;400 pg/mL</div></li></ul></li></ul></div><div id="men2.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Medullary thyroid carcinoma (MTC).</b> Standard treatment for MTC is surgical removal of the thyroid and lymph node dissection [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>, <a class="bk_pop" href="#men2.REF90">National Comprehensive Cancer Network 2015</a>]. Current NCCN guidelines recommend consideration of therapeutic external beam radiation therapy or intensity-modulated radiation therapy for incomplete tumor resection or extrathyroidal extension with positive margins [<a class="bk_pop" href="#men2.REF90">National Comprehensive Cancer Network 2015</a>]. Several kinase inhibitors &#x02013; vandetanib, cabozantinib, and BLU-667 &#x02013; have improved progression-free survival and in some cases cause disease regression in unresectable or advanced metastatic MTC [<a class="bk_pop" href="#men2.REF.elisei.2013.3639">Elisei et al 2013</a>, <a class="bk_pop" href="#men2.REF.wells.2013.3149">Wells et al 2013</a>, <a class="bk_pop" href="#men2.REF.subbiah.2018.836">Subbiah et al 2018</a>].</p><p>All individuals who have undergone thyroidectomy need thyroid hormone replacement therapy.</p><p>Autotransplantation of parathyroid tissue is not typically performed at the time of thyroidectomy unless there is evidence of hyperparathyroidism [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</p><p><b>Pheochromocytomas</b> detected by biochemical testing and radionuclide imaging are removed by adrenalectomy, which may be performed using video-assisted laparoscopy. Historically, some specialists recommended bilateral adrenalectomy at the time of demonstration of tumor on just a single adrenal gland because of the strong probability that the other adrenal gland would develop a tumor within ten years. However, because of the risk for adrenal insufficiency and Addisonian crisis following bilateral adrenalectomy, most experts now recommend unilateral adrenalectomy in unilateral tumors and cortical-sparing adrenal surgery with close monitoring of the remnant tissue in persons with one remaining adrenal gland or bilateral pheochromocytoma [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>, <a class="bk_pop" href="#men2.REF.neumann.2019.552">Neumann et al 2019</a>].</p><p>Hypertensive treatment prior to adrenalectomy often involves the use of &#x003b1;- and &#x003b2;-adrenergic receptor blockade [<a class="bk_pop" href="#men2.REF.pacak.2005.60">Pacak et al 2005</a>], although some centers do not pretreat with &#x003b1;-blockade and use nitroprusside to control blood pressure during surgery [<a class="bk_pop" href="#men2.REF.neumann.2019.552">Neumann et al 2019</a>].</p><p><b>Parathyroid adenoma or hyperplasia</b> diagnosed at the time of thyroidectomy is treated either with resection of the visibly enlarged parathyroid gland(s), subtotal parathyroidectomy, or total parathyroidectomy with forearm autograft [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>]. However, in most individuals with MEN 2A, hyperparathyroidism is diagnosed many years after thyroidectomy.</p><p>Individuals with biochemical evidence of primary hyperparathyroidism who have undergone prior thyroidectomy should have preoperative localization with excision of the localized hypertrophied parathyroid glands and forearm autotransplantation.</p><p>Therapy with medications to control primary hyperparathyroidism should be considered in individuals with a high risk for surgical mortality, limited life expectancy, or persistent or recurrent primary hyperparathyroidism after one or more surgical attempts [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</p></div><div id="men2.Prevention_of_Primary_Manifestation"><h3>Prevention of Primary Manifestations</h3><p><b>Prophylactic thyroidectomy</b> is the primary preventive measure for individuals with an identified <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#men2.REF.cohen.2003.616">Cohen &#x00026; Moley 2003</a>, <a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</p><p>Prophylactic thyroidectomy is safe for all age groups; however, the timing of the surgery is controversial [<a class="bk_pop" href="#men2.REF.moley.1998.521">Moley et al 1998</a>]. According to the American Thyroid Association Guidelines Task Force consensus statement, the age at which prophylactic thyroidectomy is performed can be guided by the codon position of the <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (see <a class="figpopup" href="/books/NBK1257/table/men2.T.risk_for_aggressive_mtc_based_on/?report=objectonly" target="object" rid-figpopup="figmen2Triskforaggressivemtcbasedon" rid-ob="figobmen2Triskforaggressivemtcbasedon">Table 3</a> and <a href="#men2.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>) [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>]. However, these guidelines continue to be modified as more data become available.</p><div id="men2.T.risk_for_aggressive_mtc_based_on" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Risk for Aggressive MTC Based on Genotype and Recommended Interventions</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1257/table/men2.T.risk_for_aggressive_mtc_based_on/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__men2.T.risk_for_aggressive_mtc_based_on_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1" style="text-align:left;vertical-align:middle;">ATA Risk Level</th><th id="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2" style="text-align:left;vertical-align:middle;">Pathogenic Variants&#x000a0;<sup>1</sup></th><th id="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_3" style="text-align:left;vertical-align:middle;">Age of Prophylactic Surgery</th><th id="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Age to Begin Screening</th></tr><tr><th headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_4" id="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">For PHEO</th><th headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_4" id="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For HPT</th></tr></thead><tbody><tr><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Level D<br />(highest risk)</td><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala883Phe<br />p.Met918Thr<br />p.[Val804Met;Glu805Lys]&#x000a0;<sup>2</sup><br />p.[Val804Met;Tyr806Cys]&#x000a0;<sup>2</sup><br />p.[Val804Met];Ser904Cys]&#x000a0;<sup>2</sup></td><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">As soon as possible in 1st year of life</td><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_4 hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8 yrs</td><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_4 hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr><tr><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Level C</td><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys634Arg<br />p.Cys634Gly<br />p.Cys634Phe<br />p.Cys634Ser<br />p.Cys634Trp<br />p.Cys634Tyr</td><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;5 yrs</td><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_4 hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8 yrs</td><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_4 hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8 yrs</td></tr><tr><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Level B</td><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys609Phe<br />p.Cys609Arg<br />p.Cys609Gly<br />p.Cys609Ser<br />p.Cys609Tyr<br />p.Cys611Arg<br />p.Cys611Gly<br />p.Cys611Phe<br />p.Cys611Ser<br />p.Cys611Trp<br />p.Cys611Tyr<br />p.Cys618Arg<br />p.Cys618Gly<br />p.Cys618Phe<br />p.Cys618Ser<br />p.Cys618Tyr<br />p.Cys620Arg<br />p.Cys620Gly<br />p.Cys620Phe<br />p.Cys620Ser<br />p.Cys620Trp<br />p.Cys620Tyr<br />p.Cys630Arg<br />p.Cys630Phe<br />p.Cys630Ser<br />p.Cys630Tyr<br />p.Asp631Tyrp.Cys634_Thr636dup (p.633/9 bp dup&#x000a0;<sup>3</sup>)<br />p.Lys634_Arg635insHisGluLeuCys (p.634/12 bp dup&#x000a0;<sup>3</sup>)<br />p.[Val804Met;Val778Ile]&#x000a0;<sup>2</sup></td><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider &#x0003c;5 yrs; may delay if criteria met&#x000a0;<sup>4</sup></td><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_4 hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Codon 630 <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>: 8 yrs<br />All others: 20 yrs</td><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_4 hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Codon 630 <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>: 8 yrs<br />All others: 20 yrs</td></tr><tr><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Level A</td><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg321Gly<br />p.Glu529_Cys531dup (p.531/9 bp dup&#x000a0;<sup>3</sup>)<br />p.Gly532dup<br />p.Cys515Ser<br />p.Gly533Cys<br />p.Arg600Gln<br />p.Lys603Glu<br />p.Tyr606Cys<br />p.635/insert ELCR;p.Thr636Pro<br />p.Lys666Glu<br />p.Glu768Asp<br />p.Asn777Ser<br />p.Leu790Phe<br />p.Val804Leu<br />p.Val804Met<br />p.Gly819Lys<br />p.Arg833Cys<br />p.Arg844Gln<br />p.Arg866Trp<br />p.Ser891Ala<br />p.Arg912Pro</td><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">May delay beyond age 5 yrs if criteria met&#x000a0;<sup>4</sup></td><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_4 hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20 yrs</td><td headers="hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_1_4 hd_h_men2.T.risk_for_aggressive_mtc_based_on_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20 yrs</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Adapted from <a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al [2009]</a></p></div></dd><dt></dt><dd><div><p class="no_margin">ATA = American Thyroid Association; HPT = hyperparathyroidism; MTC = medullary thyroid carcinoma; PHEO = pheochromocytoma</p></div></dd><dt>1. </dt><dd><div id="men2.TF.3.1"><p class="no_margin">See Molecular Genetics, <a class="figpopup" href="/books/NBK1257/table/men2.T.ret_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmen2Tretpathogenicvariantsdiscussed" rid-ob="figobmen2Tretpathogenicvariantsdiscussed">Table 5</a> for details of pathogenic variants.</p></div></dd><dt>2. </dt><dd><div id="men2.TF.3.2"><p class="no_margin">Two variants identified in a DNA sequence or a protein that derive from one <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> (<i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a>)</p></div></dd><dt>3. </dt><dd><div id="men2.TF.3.3"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>4. </dt><dd><div id="men2.TF.3.4"><p class="no_margin">Criteria: normal annual basal and or stimulated serum calcitonin; normal annual neck ultrasound examination; family history of less aggressive MTC</p></div></dd></dl></div></div></div><p><b>Thyroidectomy for C-cell hyperplasia,</b> before progression to invasive MTC, may allow surgery to be limited to thyroidectomy with sparing of lymph nodes [<a class="bk_pop" href="#men2.REF.brandi.2001.5658">Brandi et al 2001</a>, <a class="bk_pop" href="#men2.REF.kahraman.2003.331">Kahraman et al 2003</a>].</p><p><b>For all individuals with a <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> who have not had a thyroidectomy,</b> annual biochemical screening is recommended with immediate thyroidectomy if results are abnormal [<a class="bk_pop" href="#men2.REF.szinnai.2003.e132">Szinnai et al 2003</a>].</p><p><b>Annual serum calcitonin screening</b> [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>] should begin at age:</p><ul><li class="half_rhythm"><div>Six months for children with MEN 2B;</div></li><li class="half_rhythm"><div>Three to five years for children with MEN 2A or FMTC.</div></li></ul><p>Caution should be used in interpreting calcitonin results for children younger than age three years, especially those younger than age six months [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</p><p><b>Prophylactic thyroidectomy</b> is not routinely offered to at-risk individuals in whom the disorder has not been confirmed.</p></div><div id="men2.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p>Prior to any surgery, the presence of a functioning pheochromocytoma should be excluded by appropriate biochemical screening in any individual with MEN 2A or MEN 2B. In a prospective study of at-risk family members with the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, 8% had pheochromocytoma detected at the same time as MTC [<a class="bk_pop" href="#men2.REF.nguyen.2001.37">Nguyen et al 2001</a>].</p><p>If pheochromocytoma is detected, adrenalectomy should be performed before thyroidectomy to avoid intraoperative catecholamine crisis [<a class="bk_pop" href="#men2.REF.lee.2000.111">Lee &#x00026; Norton 2000</a>].</p></div><div id="men2.Surveillance"><h3>Surveillance</h3><p><b>MTC.</b> Approximately 50% of individuals diagnosed with MTC who have undergone total thyroidectomy and neck nodal dissections have recurrent disease [<a class="bk_pop" href="#men2.REF.cohen.2003.616">Cohen &#x00026; Moley 2003</a>]. Furthermore, thyroid glands removed from individuals with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> who had normal plasma calcitonin concentrations have been found to contain MTC [<a class="bk_pop" href="#men2.REF.skinner.1996.177">Skinner et al 1996</a>]. Therefore, continued monitoring for residual or recurrent MTC is indicated after thyroidectomy, even if thyroidectomy is performed prior to biochemical evidence of disease.</p><p>The screening protocol for MTC after prophylactic thyroidectomy is an annual measurement of serum calcitonin [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>]. More frequent follow up is recommended for those with residual disease.</p><p><b>Hypoparathyroidism.</b> All individuals who have undergone thyroidectomy and autotransplantation of the parathyroids need monitoring for possible hypoparathyroidism.</p><p><b>Pheochromocytoma.</b> For individuals whose initial screening results are negative for pheochromocytoma, annual biochemical screening is recommended, followed by MRI and/or CT if the biochemical results are abnormal [<a class="bk_pop" href="#men2.REF.pacak.2005.60">Pacak et al 2005</a>, <a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>, <a class="bk_pop" href="#men2.REF.neumann.2019.552">Neumann et al 2019</a>]. Women with MEN 2 should be screened for pheochromocytoma prior to a planned pregnancy, or as early as possible during an unplanned pregnancy [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>, <a class="bk_pop" href="#men2.REF.neumann.2019.552">Neumann et al 2019</a>]. Other screening studies, such as scintigraphy or positron emission tomography, may be warranted in some individuals.</p><ul><li class="half_rhythm"><div><b>MEN 2A.</b> Annual biochemical screening beginning at age eight years has been recommended for individuals with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in codons 630 and 634 and at age 20 years for a pathogenic variant in all other codons [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</div></li><li class="half_rhythm"><div><b>FMTC.</b> Screening as for MEN 2A is indicated, as not all families classified as FMTC are MTC-only [<a class="bk_pop" href="#men2.REF.moers.1996.635">Moers et al 1996</a>].</div></li><li class="half_rhythm"><div><b>MEN 2B.</b> Annual screening should begin at age eight years [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</div></li></ul><p><b>Parathyroid adenoma or hyperplasia.</b> Annual biochemical screening is recommended for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals who have not had parathyroidectomy and parathyroid autotransplantation.</p><ul><li class="half_rhythm"><div><b>MEN 2A.</b> Screening should start at age eight years for individuals with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in codons 630 and 634, and by age 20 years for individuals with other <i>RET</i> pathogenic variants [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</div></li><li class="half_rhythm"><div><b>FMTC.</b> Periodic screening should begin at age 20 years [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</div></li><li class="half_rhythm"><div><b>MEN 2B.</b> Screening is unnecessary as individuals with MEN 2B are not at increased risk for hyperparathyroidism.</div></li></ul></div><div id="men2.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Dopamine D<sub>2</sub> receptor antagonists (e.g., metoclopramide and veralipride) and &#x003b2;-adrenergic receptor antagonists (&#x003b2;-blockers) have a high potential to cause an adverse reaction in individuals with pheochromocytoma.</p><p>Other medications including monoamine oxidase inhibitors, sympathomimetics (e.g., ephedrine), and certain peptide and corticosteroid hormones may also cause complications; tricyclic antidepressants are inconsistent in causing adverse reactions [<a class="bk_pop" href="#men2.REF.eisenhofer.2007.1031">Eisenhofer et al 2007</a>].</p></div><div id="men2.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate apparently asymptomatic at-risk relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those who would benefit from initiation of treatment and preventive measures. The American Society of Clinical Oncologists (ASCO) identifies MEN 2 as a Group 1 disorder: a well-defined hereditary cancer syndrome for which genetic testing is considered part of the standard management for at-risk family members [<a class="bk_pop" href="#men2.REF1">American Society of Clinical Oncology 2003</a>]. Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known:</div><ul><li class="half_rhythm"><div><b>MEN 2A.</b>
<i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> should be offered to at-risk children by age five years. The finding of MTC in the thyroid of a 12-month-old with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> suggests that molecular genetic testing should be performed even earlier when possible [<a class="bk_pop" href="#men2.REF.machens.2004.1083">Machens et al 2004</a>].</div></li><li class="half_rhythm"><div><b>FMTC.</b> Recommendations for families with known FMTC are the same as for MEN 2A.</div></li><li class="half_rhythm"><div><b>MEN 2B.</b>
<i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> should be performed as soon as possible after birth in all children known to be at risk [<a class="bk_pop" href="#men2.REF.brandi.2001.5658">Brandi et al 2001</a>].</div></li></ul></li><li class="half_rhythm"><div>The following screening of at-risk family members if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known:</div><ul><li class="half_rhythm"><div>Neck ultrasound examination and basal and/or stimulated calcitonin measurements for MTC</div></li><li class="half_rhythm"><div>Albumin-corrected calcium or ionized calcium for hyperparathyroidism</div></li><li class="half_rhythm"><div>Measurement of plasma or 24-hour urine metanephrines and normetanephrines as appropriate [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>] for pheochromocytoma</div></li></ul></li></ul><p>See <a href="#men2.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="men2.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Women with MEN 2 should be screened for pheochromocytoma prior to a planned pregnancy, or as early as possible during an unplanned pregnancy [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</p></div><div id="men2.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Clinical trials of multikinase inhibitors such as sorafenib, sunitinib, and ponatinib are currently under way. NCCN and ATA guidelines recommend consideration of clinical trial participation for individuals who fail standard treatment with a tyrosine kinase inhibitor such as vandetanib and cabozantinib [<a class="bk_pop" href="#men2.REF90">National Comprehensive Cancer Network 2015</a>, <a class="bk_pop" href="#men2.REF.wells.2015.567">Wells et al 2015</a>]. Newer agents such as BLU-667 are showing promise as well.</p><p>Sorafenib is FDA approved for use in renal cell and hepatocellular carcinoma. In a Phase II clinical trial of sorafenib, 16 individuals with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> MTC had a partial response (1/16) or stable disease (15/16) [<a class="bk_pop" href="#men2.REF.lam.2010.2323">Lam et al 2010</a>]. A small Phase II trial of treatment with sunitinib demonstrated objective response in three (50%) of six individuals with metastatic MTC and stable disease in two individuals [<a class="bk_pop" href="#men2.REF.carr.2010.5260">Carr et al 2010</a>]. Ponatinib has been shown to inhibit RET kinase activity and diminish medullary thyroid cancer in mice [<a class="bk_pop" href="#men2.REF.de_falco.2013.e811">De Falco et al 2013</a>].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="men2.Genetic_Counseling"><h2 id="_men2_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="men2.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>All of the multiple endocrine neoplasia type 2 (MEN 2) subtypes are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="men2.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The proportion of individuals with MEN 2 who have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent varies by subtype:</p><ul><li class="half_rhythm"><div><b>MEN 2A</b></div><ul><li class="half_rhythm"><div>95% of individuals diagnosed with MEN 2A have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. The <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> for MTC, pheochromocytoma, and parathyroid disease varies by MEN 2 subtype (see <a class="figpopup" href="/books/NBK1257/table/men2.T.percent_of_clinical_features_by_m/?report=objectonly" target="object" rid-figpopup="figmen2Tpercentofclinicalfeaturesbym" rid-ob="figobmen2Tpercentofclinicalfeaturesbym">Table 2</a>).</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with MEN 2A may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of cases caused by a <i>de novo</i> germline pathogenic variant is approximately 5% [<a class="bk_pop" href="#men2.REF.schuffenecker.1997.233">Schuffenecker et al 1997</a>].</div></li><li class="half_rhythm"><div>It is appropriate to evaluate the parents of an individual with MEN 2A for manifestations of the disorder and offer <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> (see Diagnosis, <a href="#men2.Establishing_the_Diagnosis">Establishing the Diagnosis</a>).</div></li></ul></li><li class="half_rhythm"><div><b>FMTC.</b> By definition, individuals with FMTC have multiple family members who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li><li class="half_rhythm"><div><b>MEN 2B</b></div><ul><li class="half_rhythm"><div>50% of individuals diagnosed with MEN 2B have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. The <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> for MTC, pheochromocytoma, and parathyroid disease varies by MEN 2 subtype (see <a class="figpopup" href="/books/NBK1257/table/men2.T.percent_of_clinical_features_by_m/?report=objectonly" target="object" rid-figpopup="figmen2Tpercentofclinicalfeaturesbym" rid-ob="figobmen2Tpercentofclinicalfeaturesbym">Table 2</a>).</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with MEN 2B may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#men2.REF.carlson.1994.1076">Carlson et al 1994</a>]. The proportion of MEN 2B caused by a <i>de novo</i> germline <i>RET</i> pathogenic variant is 50%. The majority of <i>de novo</i> pathogenic variants are paternal in origin, but maternal origin has been reported.</div></li><li class="half_rhythm"><div>It is appropriate to evaluate the parents of an individual with MEN 2B for manifestations of the disorder and offer <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> (see Diagnosis, <a href="#men2.Establishing_the_Diagnosis">Establishing the Diagnosis</a>).</div></li></ul></li></ul><p>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, two possible explanations are <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent or a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> germline pathogenic variant in the proband. Although no instances of germline mosaicism have been reported in MEN 2, it remains a possibility.</p><p>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a clinical diagnosis of MEN 2 and an undetectable <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include thyroid ultrasound and biochemical screening for MTC, pheochromocytoma, and hyperparathyroidism.</p><p>The family history of some individuals diagnosed with MEN 2 may appear to be negative because of failure to recognize the disorder in family members, reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, early death of the parent before the onset of symptoms, or late onset of the disorder in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</p><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of inheriting the variant is 50%.</div></li><li class="half_rhythm"><div>The sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with clinically unaffected parents are still at increased risk for MEN 2 because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a parent.</div></li><li class="half_rhythm"><div>If the <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>; germline mosaicism has not been reported.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Each child of an individual with MEN 2 has a 50% chance of inheriting the <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>The probability that the offspring of an individual with <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> medullary thyroid carcinoma (MTC) (i.e., no known family history of MTC) and no identifiable <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> would inherit a <i>RET</i> pathogenic variant is 0.18% [<a class="bk_pop" href="#men2.REF.brandi.2001.5658">Brandi et al 2001</a>, <a class="bk_pop" href="#men2.REF.massoll.2004.49">Massoll &#x00026; Mazzaferri 2004</a>]. This is based on a 95% pathogenic variant detection rate and on empiric data that 7% of individuals with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> MTC have a germline <i>RET</i> pathogenic variant.</div></li></ul><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members are at increased risk.</p></div><div id="men2.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#men2.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Testing of at-risk individuals.</b> Consideration of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of at-risk family members is appropriate for surveillance (see <a href="#men2.Surveillance">Surveillance</a>). Molecular genetic testing (see <a href="#men2.Establishing_the_Diagnosis">Establishing the Diagnosis</a>) can be used for testing of at-risk relatives only if a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the family. When a known pathogenic variant is not identified, linkage analysis (see <a href="#men2.Establishing_the_Diagnosis">Establishing the Diagnosis</a>) can be considered in families with more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member from different generations. Because early detection of at-risk individuals affects medical management, testing of asymptomatic children is beneficial [<a class="bk_pop" href="#men2.REF1">American Society of Clinical Oncology 2003</a>]. Education and <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> of at-risk children and their parents prior to genetic testing are appropriate.</p><p><b>Genetic cancer risk assessment and counseling.</b> For a comprehensive description of the medical, psychosocial, and ethical ramifications of identifying at-risk individuals through cancer risk assessment with or without <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, see <a href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cancer Genetics Risk Assessment and Counseling &#x02013; health professional version</a> (part of PDQ<sup>&#x000ae;</sup>, National Cancer Institute).</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with MEN 2 has the pathogenic variant or clinical evidence of the disorder, the <i>RET</i> pathogenic variant is likely <i>de novo</i>, or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> exists. However, other possible non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="men2.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for MEN 2 are possible [<a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="men2.Resources"><h2 id="_men2_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Association for Multiple Endocrine Neoplasia Disorders (AMEND)</b></div><div>The Warehouse</div><div>No 1 Draper Street</div><div>Tunbridge Wells Kent TN4 0PG</div><div>United Kingdom</div><div><b>Phone:</b> + 44 (0)1892 516076</div><div><b>Email:</b> info@amend.org.uk</div><div><a href="http://www.amend.org.uk" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.amend.org.uk</a></div></li><li class="half_rhythm"><div><b>Associazione Italiana Neoplasie Endocrine Multiple (AIMEN 1 &#x00026; 2)</b></div><div>Corso Francia, 220/a</div><div>Italy</div><div><b>Phone:</b> 39 800 177 526</div><div><b>Fax:</b> 39 0331 983343</div><div><b>Email:</b> info@aimen.it</div><div><a href="https://aimen.it/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.aimen.it</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Familial%20Medullary%20Thyroid%20Cancer&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Familial Medullary Thyroid Cancer</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Multiple%20Endocrine%20Neoplasia%20type%202&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Multiple endocrine neoplasia type 2</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=multipleendocrineneoplasiatype1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Multiple endocrine neoplasia</a></div></li><li class="half_rhythm"><div><b>American Cancer Society (ACS)</b></div><div>250 Williams Street Northwest</div><div>Atlanta GA 30303</div><div><b>Phone:</b> 800-227-2345 (toll-free 24/7); 866-228-4327 (toll-free 24/7 TTY)</div><div><a href="http://www.cancer.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cancer.org</a></div></li><li class="half_rhythm"><div><b>CancerNetwork.com</b></div><div><a href="http://www.cancernetwork.com" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cancernetwork.com</a></div></li><li class="half_rhythm"><div><b>National Cancer Institute (NCI)</b></div><div>6116 Executive Boulevard</div><div>Suite 300</div><div>Bethesda MD 20892-8322</div><div><b>Phone:</b> 800-422-6237 (toll-free)</div><div><b>Email:</b> cancergovstaff@mail.nih.gov</div><div><a href="http://www.cancer.gov" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cancer.gov</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22207/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Multiple Endocrine Neoplasia</a></div></li><li class="half_rhythm"><div><b>PheoPara Troopers and PheoPara Alliance</b></div><div><i>To empower and support pheochromocytoma and paraganglioma patients through knowledge, a sense of community, and advocacy while sponsoring key initiatives in data collection, treatment, and patient care.</i></div><div>9721 Whitley Park Place</div><div>Bethesda MD 20814</div><div><b>Email:</b> info@pheoparatroopers.org; info@pheopara.org</div><div><a href="http://www.pheoparatroopers.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.pheoparatroopers.org</a></div></li><li class="half_rhythm"><div><b>AMEND Research Registry </b></div><div>The Warehouse</div><div>Draper Street</div><div>Tunbridge Wells Kent TN4 0PG</div><div>United Kingdom</div><div><b>Phone:</b> +44 1892 516076</div><div><b>Email:</b> jo.grey@amend.org.uk</div><div><a href="https://www.amend.org.uk/patients/research-opportunities/uk-national-men1-and-pnet-research-registry/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UK National MEN1 &#x00026; PNET Research Registry</a></div></li></ul></div><div id="men2.Molecular_Genetics"><h2 id="_men2_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="men2.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Multiple Endocrine Neoplasia Type 2: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1257/table/men2.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__men2.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_men2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_men2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_men2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_men2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_men2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_men2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_men2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5979" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>RET</i></a></td><td headers="hd_b_men2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5979" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">10q11<wbr style="display:inline-block"></wbr>​.21</a></td><td headers="hd_b_men2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P07949" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Proto-oncogene tyrosine-protein kinase receptor ret</a></td><td headers="hd_b_men2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/RET" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RET database</a></td><td headers="hd_b_men2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RET" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RET</a></td><td headers="hd_b_men2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=RET[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RET</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="men2.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="men2.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Multiple Endocrine Neoplasia Type 2 (<a href="/omim/155240,162300,164761,171400" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1257/table/men2.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__men2.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/155240" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">155240</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">THYROID CARCINOMA, FAMILIAL MEDULLARY; MTC</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/162300" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">162300</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/164761" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">164761</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">REARRANGED DURING TRANSFECTION PROTOONCOGENE; RET</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/171400" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">171400</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA; MEN2A</td></tr></tbody></table></div></div><div id="men2.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><i>RET</i> produces a receptor tyrosine kinase with extracellular, transmembrane, and intracellular domains. The extracellular <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> consists of a calcium-binding cadherin-like region and a cysteine-rich region. The encoded protein plays a role in signal transduction by interaction with the glial-derived neurotropic factor (GDNF) family of ligands: GDNF, neurturin, persephin, and artemin. Ligand interaction is via the ligand-binding GDNF family receptors (GFR&#x003b1;) to which RET protein binds the encoded protein complexes. Formation of a complex containing two RET protein molecules leads to RET autophosphorylation and intracellular signaling whereby phosphorylated tyrosines become docking sites for intracellular signaling proteins [<a class="bk_pop" href="#men2.REF.santoro.2004.5448">Santoro et al 2004</a>]. The RET tyrosine kinase catalytic core, which is located in the intracellular domain, interacts with the docking protein FRS2 and causes downstream activation of the mitogen-activated protein (MAP) kinase signaling cascade [<a class="bk_pop" href="#men2.REF.mani_.2001.580">Mani&#x000e9; et al 2001</a>]. Pathogenic variants causing MEN 2 lead to constitutive activation (i.e., gain of function) of tyrosine kinase.</p><p><b>Gene structure.</b> The <i>RET</i> proto-oncogene comprises 20 exons; the first <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> is noncoding (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_020975.5</a>). Normal tissues contain transcripts of several lengths [<a class="bk_pop" href="#men2.REF.takaya.1996.617">Takaya et al 1996</a>]. The variant <a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_020975.5</a> is the longest transcript and encodes the longer isoform (a), also known as Ret51. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1257/#men2.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Putative benign/modifier/predisposition variants.</b> Benign variants as well as variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> have been described. See <a href="/books/NBK1257/#men2.molgen.TA">Table A</a>, <b>Locus Specific</b> for a database of <i>RET</i> variants [<a class="bk_pop" href="#men2.REF.margraf.2009.548">Margraf et al 2009</a>].</p><p>It is speculated that some rare variants (e.g., p.Val648Ile) may modify the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> when inherited with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#men2.REF.nunes.2002.5658">Nunes et al 2002</a>].</p><p>Evidence suggests that other rare allelic variants may be predisposition factors. For example, p.Gly691Ser and p.Ser904= may be low-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> risk factors for development of medullary thyroid carcinoma (MTC) [<a class="bk_pop" href="#men2.REF.robledo.2003.1814">Robledo et al 2003</a>, <a class="bk_pop" href="#men2.REF.elisei.2004.3579">Elisei et al 2004</a>] and may predispose individuals with a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> to an earlier age of onset of MEN 2A [<a class="bk_pop" href="#men2.REF.gil.2002.299">Gil et al 2002</a>, <a class="bk_pop" href="#men2.REF.robledo.2003.1814">Robledo et al 2003</a>, <a class="bk_pop" href="#men2.REF.cardotbauters.2008.506">Cardot-Bauters et al 2008</a>]; however, this finding was not replicated in a larger study [<a class="bk_pop" href="#men2.REF.lesueur.2006.1177">Lesueur et al 2006</a>]. The p.Ser836= variant has been associated with an increased risk for nonfamilial MTC in at least two studies [<a class="bk_pop" href="#men2.REF.gimm.1999.1369">Gimm et al 1999</a>, <a class="bk_pop" href="#men2.REF.ruiz.2001.399">Ruiz et al 2001</a>] but not in another [<a class="bk_pop" href="#men2.REF.berard.2004.150">Berard et al 2004</a>]. A meta-analysis of six allelic variants found a modest nonfamilial MTC association with p.Ser836= and a strong association with the promoter <a class="def" href="/books/n/gene/glossary/def-item/benign-variant/">benign variant</a> IVS1-126G&#x0003e;T [<a class="bk_pop" href="#men2.REF.figlioli.2013.36">Figlioli et al 2013</a>].</p><p>Although the variants p.Ser649Leu and p.Tyr791Phe were recently reclassified as non-pathogenic, whether they act as modifiers of risk is not known [<a class="bk_pop" href="#men2.REF.erlic.2010.308">Erlic et al 2010</a>].</p><div id="men2.T.putative_ret_benignmodifierpredis" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Putative <i>RET</i> Benign/Modifier/Predisposition Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1257/table/men2.T.putative_ret_benignmodifierpredis/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__men2.T.putative_ret_benignmodifierpredis_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_men2.T.putative_ret_benignmodifierpredis_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Predicted Protein Change</th><th id="hd_h_men2.T.putative_ret_benignmodifierpredis_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DNA Nucleotide Change</th><th id="hd_h_men2.T.putative_ret_benignmodifierpredis_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_men2.T.putative_ret_benignmodifierpredis_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">p.Val648Ile</td><td headers="hd_h_men2.T.putative_ret_benignmodifierpredis_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">c.1842G&#x0003e;A</td><td headers="hd_h_men2.T.putative_ret_benignmodifierpredis_1_1_1_3" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_020975<wbr style="display:inline-block"></wbr>​.5</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_066124.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_066124<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_men2.T.putative_ret_benignmodifierpredis_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">p.Gly691Ser</td><td headers="hd_h_men2.T.putative_ret_benignmodifierpredis_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">c.2071G&#x0003e;A</td></tr><tr><td headers="hd_h_men2.T.putative_ret_benignmodifierpredis_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">p.Ser836=&#x000a0;<sup>1</sup></td><td headers="hd_h_men2.T.putative_ret_benignmodifierpredis_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">c.2508C&#x0003e;T</td></tr><tr><td headers="hd_h_men2.T.putative_ret_benignmodifierpredis_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">p.Ser904=&#x000a0;<sup>1</sup></td><td headers="hd_h_men2.T.putative_ret_benignmodifierpredis_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">c.2712C&#x0003e;G</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="men2.TF.4.1"><p class="no_margin">Designates that protein has not been analyzed, but no change in the amino acid is expected</p></div></dd></dl></div></div></div><p><b>Pathogenic variants.</b> The most common pathogenic variants are non-conservative substitutions located in one of six cysteine codons in the extracellular <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of the encoded protein. They include codons 609, 611, 618, and 620 in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 10 and codons 630 and 634 in exon 11 [<a class="bk_pop" href="#men2.REF.takahashi.1998.509">Takahashi et al 1998</a>]. All of these variants have been identified in families with MEN 2A and some have been identified in families with FMTC. Pathogenic variants in these sites have been detected in 98% of families with MEN 2A [<a class="bk_pop" href="#men2.REF.eng.1996.1575">Eng et al 1996</a>]. See <a href="/books/NBK1257/#men2.molgen.TA">Table A</a> for a database of <i>RET</i> variants [<a class="bk_pop" href="#men2.REF.margraf.2009.548">Margraf et al 2009</a>].</p><p>The risk for aggressive MTC, pheochromocytoma, and hyperparathyroidism can be estimated based on <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>. See <a class="figpopup" href="/books/NBK1257/table/men2.T.risk_for_aggressive_mtc_based_on/?report=objectonly" target="object" rid-figpopup="figmen2Triskforaggressivemtcbasedon" rid-ob="figobmen2Triskforaggressivemtcbasedon">Table 3</a> for management recommendations.</p><p>Approximately 95% of all individuals with the MEN 2B <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> have a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the tyrosine kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of <i>RET</i> at codon 918 in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 16, which substitutes a threonine for methionine [<a class="bk_pop" href="#men2.REF.eng.1996.1575">Eng et al 1996</a>]. A second pathogenic variant, <a class="figpopup" href="/books/NBK1257/table/men2.T.ret_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmen2Tretpathogenicvariantsdiscussed" rid-ob="figobmen2Tretpathogenicvariantsdiscussed">p.Ala883Phe</a>, resulting from a two-nucleotide <a class="def" href="/books/n/gene/glossary/def-item/indel/">indel</a>, has been found in 2%-3% of individuals with MEN 2B [<a class="bk_pop" href="#men2.REF.gimm.1997.3902">Gimm et al 1997</a>, <a class="bk_pop" href="#men2.REF.smith.1997.1213">Smith et al 1997</a>].</p><p>Two variants in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration on one <i>RET</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> have been reported in individuals with MEN 2B (see <a class="figpopup" href="/books/NBK1257/table/men2.T.ret_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmen2Tretpathogenicvariantsdiscussed" rid-ob="figobmen2Tretpathogenicvariantsdiscussed">Table 5</a> for codon 804 in combination with 778, 805, 806, and 904) [<a class="bk_pop" href="#men2.REF.miyauchi.1999.1">Miyauchi et al 1999</a>, <a class="bk_pop" href="#men2.REF.menko.2002.393">Menko et al 2002</a>, <a class="bk_pop" href="#men2.REF.cranston.2006.10179">Cranston et al 2006</a>, <a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>].</p><p>In addition to the pathogenic variants in the cysteine residues in exons 10 and 11 that have been found in families with MEN 2A, pathogenic variants in codons 631, 768, 790, 804, 844, and 891, and others in exons 5, 8, 10, 11, and 13-16, have been identified in a small number of families [<a class="bk_pop" href="#men2.REF.hofstra.1997.4176">Hofstra et al 1997</a>, <a class="bk_pop" href="#men2.REF.berndt.1998.770">Berndt et al 1998</a>, <a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al 2009</a>, <a class="bk_pop" href="#men2.REF.wells.2015.567">Wells et al 2015</a>].</p><p>A <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> at codon 603 was reported in one family and appeared to be associated with both MTC and papillary thyroid cancer [<a class="bk_pop" href="#men2.REF.rey.2001.390">Rey et al 2001</a>]. The pathogenic variant <a class="figpopup" href="/books/NBK1257/table/men2.T.ret_pathogenic_variants_discussed/?report=objectonly" target="object" rid-figpopup="figmen2Tretpathogenicvariantsdiscussed" rid-ob="figobmen2Tretpathogenicvariantsdiscussed">p.Arg912Pro</a> appeared to be associated with FMTC in two families [<a class="bk_pop" href="#men2.REF.jimenez.2004b.4142">Jimenez et al 2004b</a>].</p><p>Small, <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> duplications have been reported in four families [<a class="bk_pop" href="#men2.REF.h_ppner.1997.587">H&#x000f6;ppner &#x00026; Ritter 1997</a>, <a class="bk_pop" href="#men2.REF.h_ppner.1998.s128">H&#x000f6;ppner et al 1998</a>, <a class="bk_pop" href="#men2.REF.pigny.1999.1700">Pigny et al 1999</a>, <a class="bk_pop" href="#men2.REF.niccolisire.2003.1029">Niccoli-Sire et al 2003</a>].</p><p>Rare families with two pathogenic variants in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration have been reported; for example, alteration of both codons 634 and 635 in one family with MEN 2A; alteration of both codons 804 and 844 in one family with FMTC [<a class="bk_pop" href="#men2.REF.bartsch.2000.128">Bartsch et al 2000</a>]; and alteration of codons 804 and 806 in an individual with MEN 2B [<a class="bk_pop" href="#men2.REF.miyauchi.1999.1">Miyauchi et al 1999</a>].</p><p>For families in which MEN 2A and HSCR cosegregate, models to explain how the same <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can cause gain of function and loss of function have been proposed [<a class="bk_pop" href="#men2.REF.takahashi.1999.331">Takahashi et al 1999</a>].</p><div id="men2.T.ret_pathogenic_variants_discussed" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p><i>RET</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1257/table/men2.T.ret_pathogenic_variants_discussed/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__men2.T.ret_pathogenic_variants_discussed_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ATA Risk Level</th><th id="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference<br />Sequences</th></tr></thead><tbody><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_1" rowspan="5" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Level D<br />(highest risk)</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">p.Ala883Phe</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2647_2648delGCinsTT</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_4" rowspan="62" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_020975<wbr style="display:inline-block"></wbr>​.5</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_066124.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_066124<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">p.Met918Thr</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2752A&#x0003e;G</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.[Val804Met;Glu805Lys]&#x000a0;<sup>2</sup></td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.[2410G&#x0003e;T; c.2413G&#x0003e;A]&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.[Val804Met;Tyr806Cys]&#x000a0;<sup>2</sup></td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.[2410G&#x0003e;T;2417A&#x0003e;G]&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.[Val804Met;Ser904Cys]&#x000a0;<sup>2</sup></td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.[2410G&#x0003e;T;2711C&#x0003e;G]&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_1" rowspan="6" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Level C</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys634Arg</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1900C&#x0003e;T</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys634Gly</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1900T&#x0003e;G</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys634Phe</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1901G&#x0003e;T</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys634Ser</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1900T&#x0003e;A</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys634Trp</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1902C&#x0003e;G</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys634Tyr</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1901G&#x0003e;A</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_1" rowspan="30" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Level B</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys609Phe</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1826G&#x0003e;T</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys609Arg</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1825T&#x0003e;C</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys609Gly</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1825T&#x0003e;G</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys609Ser</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1825T&#x0003e;A</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys609Tyr</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1826G&#x0003e;A</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys611Arg</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1831T&#x0003e;C</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys611Gly</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1831T&#x0003e;G</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys611Phe</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1832G&#x0003e;T</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys611Ser</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1831T&#x0003e;A</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys611Trp</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1833C&#x0003e;G</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys611Tyr</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1832G&#x0003e;A</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys618Arg</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1825T&#x0003e;C</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys618Gly</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1852T&#x0003e;G</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys618Phe</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1853G&#x0003e;T</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys618Ser</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1852T&#x0003e;A</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys618Tyr</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1853G&#x0003e;A</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys620Arg</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1858T&#x0003e;C</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys620Gly</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1858T&#x0003e;G</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys620Phe</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1859G&#x0003e;T</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys620Ser</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1858T&#x0003e;A</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys620Trp</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1860C&#x0003e;G</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys620Tyr</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1859G&#x0003e;A</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys630Arg</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1888T&#x0003e;C</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys630Phe</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1889G&#x0003e;T</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys630Ser</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1889G&#x0003e;C</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys630Tyr</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1889G&#x0003e;A</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">p.Asp631Tyr</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1891G&#x0003e;T</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">p.Cys634_Thr636dup<br />(633/9 bp dup)</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1900_1908dupTGCCGCACG</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">p.Cys634_Arg635insHisGluLeuCys<br />(634/12 bp dup)</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1892_1903dupACGAGCTGTGCC</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:top;">p.[Val804Met;Val778Ile]&#x000a0;<sup>2</sup></td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.[2410G&#x0003e;T;c.2332G&#x0003e;A]&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_1" rowspan="21" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Level A</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly321Arg</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Glu529_Cys531dup<br />(531/9 bp dup)</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1585_1593dupGAGGAGTGT</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">p.Gly532dup</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">p.Cys515Ser</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Gly533Cys</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1597G&#x0003e;T</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Arg600Gln</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1799G&#x0003e;A</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Lys603Glu</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1807A&#x0003e;C</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Tyr606Cys</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1817A&#x0003e;G</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">p.635/insert ELCR;p.Thr636Pro</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Lys666Glu</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1996A&#x0003e;G</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Glu768Asp</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2304G&#x0003e;C</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Asn777Ser</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2330A&#x0003e;G</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Leu790Phe</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2379G&#x0003e;C</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Val804Leu</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2410G&#x0003e;C</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Val804Met</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2410G&#x0003e;A</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">p.Gly819Lys</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Arg833Cys</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2497C&#x0003e;T</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Arg844Gln</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2531G&#x0003e;A</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">p.Arg866Trp</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Ser891Ala</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2671T&#x0003e;G</td></tr><tr><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">p.Arg912Pro</td><td headers="hd_h_men2.T.ret_pathogenic_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2735G&#x0003e;C</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Adapted from <a class="bk_pop" href="#men2.REF.kloos.2009.565">Kloos et al [2009]</a></p></div></dd><dt></dt><dd><div><p class="no_margin">ATA = American Thyroid Association</p></div></dd><dt></dt><dd><div><p class="no_margin">See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature. <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>).</p></div></dd><dt></dt><dd><div><p class="no_margin">Variant designations are updated to current naming conventions; therefore, not all directly correlate to the nomenclature in their original publications.</p></div></dd><dt>1. </dt><dd><div id="men2.TF.5.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="men2.TF.5.2"><p class="no_margin">Two variants identified in a DNA sequence or a protein that derive from one <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> (<i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a>)</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The transcript variant <a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_020975.5</a> encodes <a href="https://www.ncbi.nlm.nih.gov/protein/NP_066124.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_066124.1</a>, the 1,114-amino acid proto-oncogene tryrosine-protein kinase receptor RET isoform (a) precursor, also known as Ret 51. For RET function, see <a href="#men2.Molecular_Pathogenesis">Molecular Pathogenesis</a>. For a detailed summary of gene, transcript, and protein information, see <a href="/books/NBK1257/#men2.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in the cysteine-rich extracellular <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (codons 609, 611, 618, 620, and 634) cause ligand-independent RET dimerization, leading to constitutive activation (i.e., gain of function) of tyrosine kinase [<a class="bk_pop" href="#men2.REF.takahashi.1998.509">Takahashi et al 1998</a>].</p><p>The <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in codon 918 that causes 95% of the MEN 2B <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> lies within the catalytic core of the tyrosine kinase and causes a constitutive activation (i.e., gain of function) of the RET kinase in its monomeric state, independent of the normal ligand-binding and dimerization steps [<a class="bk_pop" href="#men2.REF.takahashi.1998.509">Takahashi et al 1998</a>].</p><p>In contrast to the activating pathogenic variants in MEN 2, pathogenic variants that cause <a href="/books/n/gene/hirschsprung-ov/">Hirschsprung disease</a> result in a decrease in the transforming activity of RET [<a class="bk_pop" href="#men2.REF.iwashita.1996.1577">Iwashita et al 1996</a>] (see <a href="#men2.Genetically_Related_Allelic_Disorde">Genetically Related Disorders</a>).</p></div><div id="men2.Cancer_and_Benign_Tumors"><h3>Cancer and Benign Tumors</h3><p><b>Fusion proteins.</b> Approximately 20%-40% of papillary thyroid carcinoma is associated with somatic <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> rearrangements that cause juxtaposition of the tyrosine kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of <i>RET</i> to various gene partners [<a class="bk_pop" href="#men2.REF.tallini.1998.287">Tallini et al 1998</a>, <a class="bk_pop" href="#men2.REF.santoro.2002.370">Santoro et al 2002</a>, <a class="bk_pop" href="#men2.REF.puxeddu.2003.505">Puxeddu et al 2003</a>].</p><p><b>Somatic <i>RET</i> variants,</b> in the absence of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic <i>RET</i> variant, are found in medullary thyroid carcinoma of individuals without a family history of MTC and in <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> pheochromocytoma (see <a href="#men2.Differential_Diagnosis">Differential Diagnosis</a>, <b>MTC in individuals with no family history of MTC</b>; <b>Pheochromocytoma</b>).</p></div></div><div id="men2.References"><h2 id="_men2_References_">References</h2><div id="men2.Published_Guidelines__Consensus_Sta"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="men2.REF1">American Society of Clinical Oncology. Policy statement update: genetic testing for cancer susceptibility. 2003. [<a href="/pubmed/12692171" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12692171</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF2">American Society of Clinical Oncology. Policy statement update: genetic testing for cancer susceptibility. Available <a href="http://jco.ascopubs.org/content/28/5/893.long" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2010. Accessed 8-7-19.</div></li></ul></div><div id="men2.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="men2.REF.abermil.2012.e805">Abermil N, Guillaud-Bataille M, Burnichon N, Venisse A, Manivet P, Guignat L, Drui D, Chupin M, Josseaume C, Affres H, Plouin PF, Bertherat J, Jeunema&#x000ee;tre X, Gimenez-Roqueplo AP. TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2012;<span class="ref-vol">97</span>:E805–9.</span> [<a href="/pubmed/22419703" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22419703</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.aiello.2005.574">Aiello A, Cioni K, Gobbo M, Collini P, Gullo M, Della Torre G, Passerini E, Ferrando B, Pilotti S, Pierotti MA, Pasini B. The familial medullary thyroid carcinoma-associated RET E768D mutation in a multiple endocrine neoplasia type 2A case. <span><span class="ref-journal">Surgery. </span>2005;<span class="ref-vol">137</span>:574–6.</span> [<a href="/pubmed/15855933" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15855933</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.american_society_of_clinical_oncology.2003.2397">American Society of Clinical Oncology.  American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. <span><span class="ref-journal">J Clin Oncol. </span>2003;<span class="ref-vol">21</span>:2397–406.</span> [<a href="/pubmed/12692171" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12692171</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.bartsch.2000.128">Bartsch DK, Hasse C, Schug C, Barth P, Rothmund M, H&#x000f6;ppner W. A RET double mutation in the germline of a kindred with FMTC. <span><span class="ref-journal">Exp Clin Endocrinol Diabetes. </span>2000;<span class="ref-vol">108</span>:128–32.</span> [<a href="/pubmed/10826520" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10826520</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.bayley.2010.366">Bayley JP, Kunst HP, Casc&#x000f3;n A, Sampietro ML, Gaal J, Korpershoek E, Hinojar-Gutierrez A, Timmers HJ, Hoefsloot LH, Hermsen MA, Su&#x000e1;rez C, Hussain AK, Vriends AH, Hes FJ, Jansen JC, Tops CM, Corssmit EP, de Knijff P, Lenders JW, Cremers CW, Devilee P, Dinjens WN, de Krijger RR, Robledo M. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. <span><span class="ref-journal">Lancet Oncol. </span>2010;<span class="ref-vol">11</span>:366–72.</span> [<a href="/pubmed/20071235" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20071235</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.berard.2004.150">Berard I, Kraimps JL, Savagner F, Murat A, Renaudin K, Nicolli-Sire P, Bertrand G, Moisan JP, Bezieau S. Germline-sequence variants S836S and L769L in the RE arranged during Transfection (RET) proto-oncogene are not associated with predisposition to sporadic medullary carcinoma in the French population. <span><span class="ref-journal">Clin Genet. </span>2004;<span class="ref-vol">65</span>:150–2.</span> [<a href="/pubmed/14984475" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14984475</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.berndt.1998.770">Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grussendorf M, Raue F, Ritter MM, H&#x000f6;ppner W. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>1998;<span class="ref-vol">83</span>:770–4.</span> [<a href="/pubmed/9506724" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9506724</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.boedeker.2009.1938">Boedeker CC, Erlic Z, Richard S, Kontny U, Gimenez-Roqueplo AP, Casc&#x000f3;n A, Robledo M, de Campos JM, van Nederveen FH, de Krijger RR, Burnichon N, Gaal J, Walter MA, Reschke K, Wiech T, Weber J, R&#x000fc;ckauer K, Plouin PF, Darrouzet V, Giraud S, Eng C, Neumann HP. Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2009;<span class="ref-vol">94</span>:1938–44.</span> [<a href="/pmc/articles/PMC2690424/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2690424</span></a>] [<a href="/pubmed/19336503" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19336503</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.brandi.2001.5658">Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ. Guidelines for diagnosis and therapy of MEN type 1 and type 2. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2001;<span class="ref-vol">86</span>:5658–71.</span> [<a href="/pubmed/11739416" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11739416</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.brauckhoff.2002.557">Brauckhoff M, Gimm O, Hinze R, Ukkat J, Brauckhoff K, Dralle H. Papillary thyroid carcinoma in patients with RET proto-oncogene germline mutation. <span><span class="ref-journal">Thyroid. </span>2002;<span class="ref-vol">12</span>:557–61.</span> [<a href="/pubmed/12193298" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12193298</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.brenner.2008.1117">Brenner ME, Jacene HA. Recurrent or residual hyperparathyroidism and thyroid cancer effectively evaluated with scintigraphy. <span><span class="ref-journal">Otolaryngol Clin North Am. </span>2008;<span class="ref-vol">41</span>:1117–33.</span> [<a href="/pubmed/19040973" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19040973</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.bryant.2003.1196">Bryant J, Farmer J, Kessler LJ, Townsend RR, Nathanson KL. Pheochromocytoma: the expanding genetic differential diagnosis. <span><span class="ref-journal">J Natl Cancer Inst. </span>2003;<span class="ref-vol">95</span>:1196–204.</span> [<a href="/pubmed/12928344" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12928344</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.buffet.2018.1914">Buffet A, Morin A, Castro-Vega LJ, Habarou F, Lussey-Lepoutre C, Letouz&#x000e9; E, Lefebvre H, Guilhem I, Haissaguerre M, Raingeard I, Padilla-Girola M, Tran T, Tchara L, Bertherat J, Amar L, Ottolenghi C, Burnichon N, Gimenez-Roqueplo AP, Favier J. Germline mutations in the mitochondrial 2-oxoglutarate/malate carrier SLC25A11 gene confer a predisposition to metastatic paragangliomas. <span><span class="ref-journal">Cancer Res. </span>2018;<span class="ref-vol">78</span>:1914–22.</span> [<a href="/pubmed/29431636" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29431636</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.burnichon.2010.3011">Burnichon N, Bri&#x000e8;re JJ, Lib&#x000e9; R, Vescovo L, Rivi&#x000e8;re J, Tissier F, Jouanno E, Jeunemaitre X, B&#x000e9;nit P, Tzagoloff A, Rustin P, Bertherat J, Favier J, Gimenez-Roqueplo AP. SDHA is a tumor suppressor gene causing paraganglioma. <span><span class="ref-journal">Hum Mol Genet. </span>2010;<span class="ref-vol">19</span>:3011–20.</span> [<a href="/pmc/articles/PMC2901140/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2901140</span></a>] [<a href="/pubmed/20484225" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20484225</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.burnichon.2012a.5397">Burnichon N, Buffet A, Parfait B, Letouz&#x000e9; E, Laurendeau I, Loriot C, Pasmant E, Abermil N, Valeyrie-Allanore L, Bertherat J, Amar L, Vidaud D, Favier J, Gimenez-Roqueplo AP. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. <span><span class="ref-journal">Hum Mol Genet. </span>2012a;<span class="ref-vol">21</span>:5397–405.</span> [<a href="/pubmed/22962301" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22962301</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.burnichon.2012b.2828">Burnichon N, Casc&#x000f3;n A, Schiavi F, Morales NP, Comino-M&#x000e9;ndez I, Abermil N, Inglada-P&#x000e9;rez L, de Cubas AA, Amar L, Barontini M, de Quir&#x000f3;s SB, Bertherat J, Bignon YJ, Blok MJ, Bobisse S, Borrego S, Castellano M, Chanson P, Chiara MD, Corssmit EP, Giacch&#x000e8; M, de Krijger RR, Ercolino T, Girerd X, G&#x000f3;mez-Garc&#x000ed;a EB, G&#x000f3;mez-Gra&#x000f1;a A, Guilhem I, Hes FJ, Honrado E, Korpershoek E, Lenders JW, Let&#x000f3;n R, Mensenkamp AR, Merlo A, Mori L, Murat A, Pierre P, Plouin PF, Prodanov T, Quesada-Charneco M, Qin N, Rapizzi E, Raymond V, Reisch N, Roncador G, Ruiz-Ferrer M, Schillo F, Stegmann AP, Suarez C, Taschin E, Timmers HJ, Tops CM, Urioste M, Beuschlein F, Pacak K, Mannelli M, Dahia PL, Opocher G, Eisenhofer G, Gimenez-Roqueplo AP, Robledo M. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. <span><span class="ref-journal">Clin Cancer Res. </span>2012b;<span class="ref-vol">18</span>:2828–37.</span> [<a href="/pubmed/22452945" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22452945</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.burnichon.2009.2817">Burnichon N, Rohmer V, Amar L, Herman P, Leboulleux S, Darrouzet V, Niccoli P, Gaillard D, Chabrier G, Chabolle F, Coupier I, Thieblot P, Lecomte P, Bertherat J, Wion-Barbot N, Murat A, Venisse A, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP, et al.  The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2009;<span class="ref-vol">94</span>:2817–27.</span> [<a href="/pubmed/19454582" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19454582</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.callender.2008.863">Callender GG, Rich TA, Perrier ND. Multiple endocrine neoplasia syndromes. <span><span class="ref-journal">Surg Clin North Am. </span>2008;<span class="ref-vol">88</span>:863–95.</span> [<a href="/pubmed/18672144" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18672144</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.cardotbauters.2008.506">Cardot-Bauters C, Leteurtre E, Leclerc L, Vantyghem MC, Do Cao C, Wemeau JL, d'Herbomez M, Carnaille B, Barbu V, Pinson S, Pigny P, et al.  Does the RET variant G691S influence the features of sporadic medullary thyroid carcinoma? <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2008;<span class="ref-vol">69</span>:506–10.</span> [<a href="/pubmed/18331611" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18331611</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.carlson.1994.1076">Carlson KM, Bracamontes J, Jackson CE, Clark R, Lacroix A, Wells SA Jr, Goodfellow PJ. Parent-of-origin effects in multiple endocrine neoplasia type 2B. <span><span class="ref-journal">Am J Hum Genet. </span>1994;<span class="ref-vol">55</span>:1076–82.</span> [<a href="/pmc/articles/PMC1918453/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1918453</span></a>] [<a href="/pubmed/7977365" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7977365</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.carr.2010.5260">Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. <span><span class="ref-journal">Clin Cancer Res. </span>2010;<span class="ref-vol">16</span>:5260–8.</span> [<a href="/pmc/articles/PMC3063514/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3063514</span></a>] [<a href="/pubmed/20847059" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20847059</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.casc_n.2015.107">Casc&#x000f3;n A, Comino-Mendez I, Curras-Freixes M, de Cubas AA, Contreras L, Richter S, Peitzsch M, Mancikova V, Inglada-P&#x000e9;rez L, P&#x000e9;rez-Barrios A, Calatayud M, Azriel S, Villar-Vicente R, Aller J, Seti&#x000e9;n F, Moran S, Garcia JF, R&#x000ed;o-Mach&#x000ed;n A, Let&#x000f3;n R, G&#x000f3;mez-Gra&#x000f1;a &#x000c1;, Apell&#x000e1;niz-Ruiz M, Roncador G, Esteller M, Rodr&#x000ed;guez-Antona C, Satr&#x000fa;stegui J, Eisenhofer G, Urioste M, Robledo M. Whole-exome sequencing identifies <em>MDH2</em> as a new familial paraganglioma gene. <span><span class="ref-journal">J Natl Cancer Inst. </span>2015:107.</span> [<a href="/pubmed/25766404" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25766404</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.castinetti.2019.213">Castinetti F, Waguespack S, Machens A, Uchino S, Lazar K, Sanso G, Else T, Dvorakova S, Qi XP, Elisei R, Maia AL, Glod J, Muniz D, Valdes N, Mathiesen J, Wohllk N, Bangdar T, Delphine D, Korbonits M, Druce M, Brain C, Kurzawinki T, Patocs A, Bugalho MJ, Lacroix A, Phillippe C, Fainstein-Day P, Borson-Chazot F, Klein M, Links T, Letizia C, Fugazzola L, Chabre O, Canu L, Cohen R, Tabarin A, Spehar A, Maiter D, Laboureau S, Mian C, Peczkowska M, Sebag F, Brue T, Prunier D, Leclerc L, Bausch B, Barontini M, Ferreira CV, Valerio L, Ceolin L, Akshintala S, Hoff A, Godballe C, Jarzab B, Jimenez C, Imai T, Eng C, Schlumberger M, Grubbs E, Dralle H, Neumann HP, Baudin E. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. <span><span class="ref-journal">Lancet Diabetes Endocrinol. </span>2019;<span class="ref-vol">7</span>:213–20.</span> [<a href="/pubmed/30660595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30660595</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.castrovega.2014.2440">Castro-Vega LJ, Buffet A, De Cubas AA, Casc&#x000f3;n A, Menara M, Khalifa E, Amar L, Azriel S, Bourdeau I, Chabre O, Curr&#x000e1;s-Freixes M, Franco-Vidal V, Guillaud-Bataille M, Simian C, Morin A, Let&#x000f3;n R, G&#x000f3;mez-Gra&#x000f1;a A, Pollard PJ, Rustin P, Robledo M, Favier J, Gimenez-Roqueplo AP. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. <span><span class="ref-journal">Hum Mol Genet. </span>2014;<span class="ref-vol">23</span>:2440–6.</span> [<a href="/pubmed/24334767" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24334767</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.cohen.2003.616">Cohen MS, Moley JF. Surgical treatment of medullary thyroid carcinoma. <span><span class="ref-journal">J Intern Med. </span>2003;<span class="ref-vol">253</span>:616–26.</span> [<a href="/pubmed/12755957" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12755957</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.cominom_ndez.2011.663">Comino-M&#x000e9;ndez I, Gracia-Azn&#x000e1;rez FJ, Schiavi F, Landa I, Leandro-Garc&#x000ed;a LJ, Let&#x000f3;n R, Honrado E, Ramos-Medina R, Caronia D, Pita G, G&#x000f3;mez-Gra&#x000f1;a A, de Cubas AA, Inglada-P&#x000e9;rez L, Maliszewska A, Taschin E, Bobisse S, Pica G, Loli P, Hern&#x000e1;ndez-Lavado R, D&#x000ed;az JA, G&#x000f3;mez-Morales M, Gonz&#x000e1;lez-Neira A, Roncador G, Rodr&#x000ed;guez-Antona C, Ben&#x000ed;tez J, Mannelli M, Opocher G, Robledo M, Casc&#x000f3;n A. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. <span><span class="ref-journal">Nat Genet. </span>2011;<span class="ref-vol">43</span>:663–7.</span> [<a href="/pubmed/21685915" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21685915</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.costante.2009.35">Costante G, Durante C, Francis Z, Schlumberger M, Filetti S. Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. <span><span class="ref-journal">Nat Clin Pract Endocrinol Metab. </span>2009;<span class="ref-vol">5</span>:35–44.</span> [<a href="/pubmed/19079272" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19079272</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.costante.2007.450">Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M, Filetti S. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2007;<span class="ref-vol">92</span>:450–5.</span> [<a href="/pubmed/17119000" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17119000</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.cranston.2006.10179">Cranston AN, Carniti C, Oakhill K, Radzio-Andzelm E, Stone EA, McCallion AS, Hodgson S, Clarke S, Mondellini P, Leyland J, Pierotti MA, Whittaker J, Taylor SS, Bongarzone I, Ponder BA. RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. <span><span class="ref-journal">Cancer Res. </span>2006;<span class="ref-vol">66</span>:10179–87.</span> [<a href="/pubmed/17047083" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17047083</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.decker.1998.129">Decker RA, Peacock ML, Watson P. Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. <span><span class="ref-journal">Hum Mol Genet. </span>1998;<span class="ref-vol">7</span>:129–34.</span> [<a href="/pubmed/9384613" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9384613</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.de_falco.2013.e811">De Falco V, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M, Gozgit JM, Carlomagno F, Santoro M. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2013;<span class="ref-vol">98</span>:E811–9.</span> [<a href="/pubmed/23526464" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23526464</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.de_groot.2006.535">de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. <span><span class="ref-journal">Endocr Rev. </span>2006;<span class="ref-vol">27</span>:535–60.</span> [<a href="/pubmed/16849421" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16849421</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.delellis.2004">DeLellis RA, Lloyd RV, Heitz PU, Eng C. <em>Pathology and Genetics: Tumours of the Endocrine Organs. World Health Organization Classification of Tumours Series.</em> Vol 8. Lyon, France: IARC Press; 2004.</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.dvorakova.2008.21">Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J, Ryska A, Laco J, Cap J, Kodetova D, Kodet R, Krskova L, Vlcek P, Astl J, Vesely D, Bendlova B. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. <span><span class="ref-journal">Mol Cell Endocrinol. </span>2008;<span class="ref-vol">284</span>:21–7.</span> [<a href="/pubmed/18282654" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18282654</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.eisenhofer.2007.1031">Eisenhofer G, Rivers G, Rosas AL, Quezado Z, Manger WM, Pacak K. Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. <span><span class="ref-journal">Drug Saf. </span>2007;<span class="ref-vol">30</span>:1031–62.</span> [<a href="/pubmed/17973541" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17973541</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.elisei.2008.682">Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2008;<span class="ref-vol">93</span>:682–7.</span> [<a href="/pubmed/18073307" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18073307</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.elisei.2004.3579">Elisei R, Cosci B, Romei C, Bottici V, Sculli M, Lari R, Barale R, Pacini F, Pinchera A. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2004;<span class="ref-vol">89</span>:3579–84.</span> [<a href="/pubmed/15240649" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15240649</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.elisei.2007.4725">Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, Pacini F, Pinchera A. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2007;<span class="ref-vol">92</span>:4725–9.</span> [<a href="/pubmed/17895320" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17895320</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.elisei.2013.3639">Elisei R, Schlumberger MJ, M&#x000fc;ller SP, Sch&#x000f6;ffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. <span><span class="ref-journal">J Clin Oncol. </span>2013;<span class="ref-vol">31</span>:3639–46.</span> [<a href="/pmc/articles/PMC4164813/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4164813</span></a>] [<a href="/pubmed/24002501" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24002501</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.eng.1996.1575">Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskj&#x000f6;ld M, Komminoth P, Hendy GN, Mulligan LM. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. <span><span class="ref-journal">JAMA. </span>1996;<span class="ref-vol">276</span>:1575–9.</span> [<a href="/pubmed/8918855" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8918855</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.erlic.2010.308">Erlic Z, Hoffmann MM, Sullivan M, Franke G, Peczkowska M, Harsch I, Schott M, Gabbert HE, Valim&#x000e4;ki M, Preuss SF, Hasse-Lazar K, Waligorski D, Robledo M, Januszewicz A, Eng C, Neumann HP. Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2010;<span class="ref-vol">95</span>:308–13.</span> [<a href="/pmc/articles/PMC2805484/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2805484</span></a>] [<a href="/pubmed/19906784" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19906784</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.erlic.2009.6378">Erlic Z, Rybicki L, Peczkowska M, Golcher H, Kann PH, Brauckhoff M, M&#x000fc;ssig K, Muresan M, Sch&#x000e4;ffler A, Reisch N, Schott M, Fassnacht M, Opocher G, Klose S, Fottner C, Forrer F, Pl&#x000f6;ckinger U, Petersenn S, Zabolotny D, Kollukch O, Yaremchuk S, Januszewicz A, Walz MK, Eng C, Neumann HP, et al.  Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. <span><span class="ref-journal">Clin Cancer Res. </span>2009;<span class="ref-vol">15</span>:6378–85.</span> [<a href="/pubmed/19825962" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19825962</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.feldman.2000.93">Feldman GL, Edmonds MW, Ainsworth PJ, Schuffenecker I, Lenoir GM, Saxe AW, Talpos GB, Roberson J, Petrucelli N, Jackson CE. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG--&#x0003e;ATG) mutation. <span><span class="ref-journal">Surgery. </span>2000;<span class="ref-vol">128</span>:93–8.</span> [<a href="/pubmed/10876191" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10876191</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.figlioli.2013.36">Figlioli G, Landi S, Romei C, Elisei R, Gemignani F. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. <span><span class="ref-journal">Mutat Res. </span>2013;<span class="ref-vol">752</span>:36–44.</span> [<a href="/pubmed/23059849" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23059849</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.fishbein.2013.1444">Fishbein L, Merrill S, Fraker DL, Cohen DL, Nathanson KL. Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. <span><span class="ref-journal">Ann Surg Oncol. </span>2013;<span class="ref-vol">20</span>:1444–50.</span> [<a href="/pmc/articles/PMC4291281/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4291281</span></a>] [<a href="/pubmed/23512077" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23512077</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.frohnauer.2000.1052">Frohnauer MK, Decker RA. Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated? <span><span class="ref-journal">Surgery. </span>2000;<span class="ref-vol">128</span>:1052–7.</span> [<a href="/pubmed/11114642" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11114642</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.gibelin.2004.1458">Gibelin H, Bezieau S, Misso C, Bouin-Pineau MH, Mar&#x000e9;chaud R, Kraimps JL. Germline RET V804M mutation associated with multiple endocrine neoplasia type 2A. <span><span class="ref-journal">Br J Surg. </span>2004;<span class="ref-vol">91</span>:1458–9.</span> [<a href="/pubmed/15386323" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15386323</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.gil.2002.299">Gil L, Aza&#x000f1;edo M, Poll&#x000e1;n M, Cristobal E, Arribas B, Garc&#x000ed;a-Albert L, Garc&#x000ed;a-S&#x000e1;iz A, Maestro ML, Torres A, Men&#x000e1;rguez J, Rojas JM. Genetic analysis of RET, GFR alpha 1 and GDNF genes in Spanish families with multiple endocrine neoplasia type 2A. <span><span class="ref-journal">Int J Cancer. </span>2002;<span class="ref-vol">99</span>:299–304.</span> [<a href="/pubmed/11979448" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11979448</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.gimm.1997.3902">Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PL, Mulligan LM, Zajac JD, Robinson BG, Eng C. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>1997;<span class="ref-vol">82</span>:3902–4.</span> [<a href="/pubmed/9360560" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9360560</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.gimm.1999.1369">Gimm O, Neuberg DS, Marsh DJ, Dahia PL, Hoang-Vu C, Raue F, Hinze R, Dralle H, Eng C. Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. <span><span class="ref-journal">Oncogene. </span>1999;<span class="ref-vol">18</span>:1369–73.</span> [<a href="/pubmed/10022819" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10022819</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.giraud.1998.455">Giraud S, Zhang CX, Serova-Sinilnikova O, Wautot V, Salandre J, Buisson N, Waterlot C, Bauters C, Porchet N, Aubert JP, Emy P, Cadiot G, Delemer B, Chabre O, Niccoli P, Leprat F, Duron F, Emperauger B, Cougard P, Goudet P, Sarfati E, Riou JP, Guichard S, Rodier M, Meyrier A, Caron P, Vantyghem MC, Assayag M, Peix JL, Pugeat M, Rohmer V, Vallotton M, Lenoir G, Gaudray P, Proye C, Conte-Devolx B, Chanson P, Shugart YY, Goldgar D, Murat A, Calender A. Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">63</span>:455–67.</span> [<a href="/pmc/articles/PMC1377295/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377295</span></a>] [<a href="/pubmed/9683585" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9683585</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.hansford.2000.817">Hansford JR, Mulligan LM. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. <span><span class="ref-journal">J Med Genet. </span>2000;<span class="ref-vol">37</span>:817–27.</span> [<a href="/pmc/articles/PMC1734482/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1734482</span></a>] [<a href="/pubmed/11073534" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11073534</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.hofstra.1997.4176">Hofstra RM, Fattoruso O, Quadro L, Wu Y, Libroia A, Verga U, Colantuoni V, Buys CH. A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>1997;<span class="ref-vol">82</span>:4176–8.</span> [<a href="/pubmed/9398735" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9398735</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.h_ie.2000.3249">H&#x000f8;ie J, Heimdal K, Nesland JM, B&#x000f8;rmer O. Prophylactic thyroidectomy in carriers of RET oncogene mutation carriers. <span><span class="ref-journal">Tidsskr Nor Laegeforen. </span>2000;<span class="ref-vol">120</span>:3249–52.</span> [<a href="/pubmed/11187163" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11187163</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.h_ppner.1998.s128">H&#x000f6;ppner W, Dralle H, Brabant G. Duplication of 9 base pairs in the critical cysteine-rich domain of the RET proto-oncogene causes multiple endocrine neoplasia type 2A. <span><span class="ref-journal">Hum Mutat. </span>1998 Suppl 1:S128–30.</span> [<a href="/pubmed/9452064" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9452064</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.h_ppner.1997.587">H&#x000f6;ppner W, Ritter MM. A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. <span><span class="ref-journal">Hum Mol Genet. </span>1997;<span class="ref-vol">6</span>:587–90.</span> [<a href="/pubmed/9097963" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9097963</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.ilias.2008.1613">Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Laz&#x000fa;rov&#x000e1; I, Adams KT, Perera S, Pacak K. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. <span><span class="ref-journal">J Nucl Med. </span>2008;<span class="ref-vol">49</span>:1613–9.</span> [<a href="/pmc/articles/PMC2614907/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2614907</span></a>] [<a href="/pubmed/18794260" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18794260</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.ilias.2009.89">Ilias I, Pacak K. Diagnosis, localization and treatment of pheochromocytoma in MEN 2 syndrome. <span><span class="ref-journal">Endocr Regul. </span>2009;<span class="ref-vol">43</span>:89–93.</span> [<a href="/pubmed/19856714" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19856714</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.inabnet.2000.1007">Inabnet WB, Caragliano P, Pertsemlidis D. Pheochromocytoma: inherited associations, bilaterality, and cortex preservation. <span><span class="ref-journal">Surgery. </span>2000;<span class="ref-vol">128</span>:1007–11.</span> [<a href="/pubmed/11114636" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11114636</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.inoue.1999.1552">Inoue K, Shimotake T, Inoue K, Tokiwa K, Iwai N. Mutational analysis of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease. <span><span class="ref-journal">J Pediatr Surg. </span>1999;<span class="ref-vol">34</span>:1552–4.</span> [<a href="/pubmed/10549772" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10549772</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.iwashita.1996.1577">Iwashita T, Murakami H, Asai N, Takahashi M. Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain. <span><span class="ref-journal">Hum Mol Genet. </span>1996;<span class="ref-vol">5</span>:1577–80.</span> [<a href="/pubmed/8894691" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8894691</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.jimenez.2004a.3521">Jimenez C, Dang GT, Schultz PN, El-Naggar A, Shapiro S, Barnes EA, Evans DB, Vassilopoulou-Sellin R, Gagel RF, Cote GJ, Hoff AO. A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2004a;<span class="ref-vol">89</span>:3521–6.</span> [<a href="/pubmed/15240641" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15240641</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.jimenez.2004b.4142">Jimenez C, Habra MA, Huang SC, El-Naggar A, Shapiro SE, Evans DB, Cote G, Gagel RF. Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2004b;<span class="ref-vol">89</span>:4142–5.</span> [<a href="/pubmed/15292360" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15292360</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.kahraman.2003.331">Kahraman T, de Groot JW, Rouwe C, Hofstra RM, Links TP, Sijmons RH, Plukker JT. Acceptable age for prophylactic surgery in children with multiple endocrine neoplasia type 2a. <span><span class="ref-journal">Eur J Surg Oncol. </span>2003;<span class="ref-vol">29</span>:331–5.</span> [<a href="/pubmed/12711285" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12711285</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.kloos.2009.565">Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr. Medullary thyroid cancer: management guidelines of the American Thyroid Association. <span><span class="ref-journal">Thyroid. </span>2009;<span class="ref-vol">19</span>:565–612.</span> [<a href="/pubmed/19469690" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19469690</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.korpershoek.2011.e1472">Korpershoek E, Favier J, Gaal J, Burnichon N, van Gessel B, Oudijk L, Badoual C, Gadessaud N, Venisse A, Bayley JP, van Dooren MF, de Herder WW, Tissier F, Plouin PF, van Nederveen FH, Dinjens WN, Gimenez-Roqueplo AP, de Krijger RR. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2011;<span class="ref-vol">96</span>:E1472–6.</span> [<a href="/pubmed/21752896" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21752896</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.kouvaraki.2005.531">Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. <span><span class="ref-journal">Thyroid. </span>2005;<span class="ref-vol">15</span>:531–44.</span> [<a href="/pubmed/16029119" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16029119</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.lam.2010.2323">Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. <span><span class="ref-journal">J Clin Oncol. </span>2010;<span class="ref-vol">28</span>:2323–30.</span> [<a href="/pmc/articles/PMC2881718/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2881718</span></a>] [<a href="/pubmed/20368568" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20368568</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.lecube.2002.509">Lecube A, Hernandez C, Oriola J, Galard R, G&#x000e9;mar E, Mesa J, Sim&#x000f3; R. V804M RET mutation and familial medullary thyroid carcinoma: report of a large family with expression of the disease only in the homozygous gene carriers. <span><span class="ref-journal">Surgery. </span>2002;<span class="ref-vol">131</span>:509–14.</span> [<a href="/pubmed/12019403" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12019403</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.lee.2013.781">Lee M, Pellegata NS. Multiple endocrine neoplasia syndromes associated with mutation of p27. <span><span class="ref-journal">J Endocrinol Invest. </span>2013;<span class="ref-vol">36</span>:781–7.</span> [<a href="/pubmed/23800691" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23800691</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.lee.2000.111">Lee NC, Norton JA. Multiple endocrine neoplasia type 2B--genetic basis and clinical expression. <span><span class="ref-journal">Surg Oncol. </span>2000;<span class="ref-vol">9</span>:111–8.</span> [<a href="/pubmed/11356339" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11356339</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.lesueur.2006.1177">Lesueur F, Cebrian A, Robledo M, Niccoli-Sire P, Svensson KA, Pinson S, Leyland J, Whittaker J, Pharoah PD, Ponder BA. Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A. <span><span class="ref-journal">Cancer Res. </span>2006;<span class="ref-vol">66</span>:1177–80.</span> [<a href="/pubmed/16424056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16424056</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.lorenzo.2013.507">Lorenzo FR, Yang C, Ng Tang Fui M, Vankayalapati H, Zhuang Z, Huynh T, Grossmann M, Pacak K, Prchal JT. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. <span><span class="ref-journal">J Mol Med (Berl). </span>2013;<span class="ref-vol">91</span>:507–12.</span> [<a href="/pmc/articles/PMC3570726/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3570726</span></a>] [<a href="/pubmed/23090011" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23090011</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.machens.2006.34">Machens A, Dralle H. Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside. <span><span class="ref-journal">Mol Cell Endocrinol. </span>2006;<span class="ref-vol">247</span>:34–40.</span> [<a href="/pubmed/16343738" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16343738</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.machens.2001.1104">Machens A, Gimm O, Hinze R, H&#x000f6;ppner W, Boehm BO, Dralle H. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2001;<span class="ref-vol">86</span>:1104–9.</span> [<a href="/pubmed/11238493" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11238493</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.machens.2003.1517">Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, Dralle H, et al.  Early malignant progression of hereditary medullary thyroid cancer. <span><span class="ref-journal">N Engl J Med. </span>2003;<span class="ref-vol">349</span>:1517–25.</span> [<a href="/pubmed/14561794" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14561794</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.machens.2004.1083">Machens A, Schneyer U, Holzhausen HJ, Raue F, Dralle H. Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation. <span><span class="ref-journal">Surgery. </span>2004;<span class="ref-vol">136</span>:1083–7.</span> [<a href="/pubmed/15523405" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15523405</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.mani_.2001.580">Mani&#x000e9; S, Santoro M, Fusco A, Billaud M. The RET receptor: function in development and dysfunction in congenital malformation. <span><span class="ref-journal">Trends Genet. </span>2001;<span class="ref-vol">17</span>:580–9.</span> [<a href="/pubmed/11585664" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11585664</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.margraf.2009.548">Margraf RL, Crockett DK, Krautscheid PM, Seamons R, Calderon FR, Wittwer CT, Mao R. Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. <span><span class="ref-journal">Hum Mutat. </span>2009;<span class="ref-vol">30</span>:548–56.</span> [<a href="/pubmed/19177457" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19177457</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.massoll.2004.49">Massoll N, Mazzaferri EL. Diagnosis and management of medullary thyroid carcinoma. <span><span class="ref-journal">Clin Lab Med. </span>2004;<span class="ref-vol">24</span>:49–83.</span> [<a href="/pubmed/15157557" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15157557</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.menko.2002.393">Menko FH, van der Luijt RB, de Valk IA, Toorians AW, Sepers JM, van Diest PJ, Lips CJ. Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2002;<span class="ref-vol">87</span>:393–7.</span> [<a href="/pubmed/11788682" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11788682</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.miyauchi.1999.1">Miyauchi A, Futami H, Hai N, Yokozawa T, Kuma K, Aoki N, Kosugi S, Sugano K, Yamaguchi K. Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. <span><span class="ref-journal">Jpn J Cancer Res. </span>1999;<span class="ref-vol">90</span>:1–5.</span> [<a href="/pmc/articles/PMC5925979/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5925979</span></a>] [<a href="/pubmed/10076558" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10076558</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.modigliani.1995.363">Modigliani E, Vasen HM, Raue K, Dralle H, Frilling A, Gheri RG, Brandi ML, Limbert E, Niederle B, Forgas L, Rosenberg-Bourgin M, Calmettes C. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. <span><span class="ref-journal">J Intern Med. </span>1995;<span class="ref-vol">238</span>:363–7.</span> [<a href="/pubmed/7595173" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7595173</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.moers.1996.635">Moers AM, Landsvater RM, Schaap C, Jansen-Schillhorn van Veen JM, de Valk IA, Blijham GH, H&#x000f6;ppener JW, Vroom TM, van Amstel HK, Lips CJ. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. <span><span class="ref-journal">Am J Med. </span>1996;<span class="ref-vol">101</span>:635–41.</span> [<a href="/pubmed/9003111" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9003111</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.moley.1998.521">Moley JF, Debenedetti MK, Dilley WG, Tisell LE, Wells SA. Surgical management of patients with persistent or recurrent medullary thyroid cancer. <span><span class="ref-journal">J Intern Med. </span>1998;<span class="ref-vol">243</span>:521–6.</span> [<a href="/pubmed/9681853" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9681853</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.morrison.1996.779">Morrison PJ, Nevin NC. Multiple endocrine neoplasia type 2B (mucosal neuroma syndrome, Wagenmann-Froboese syndrome). <span><span class="ref-journal">J Med Genet. </span>1996;<span class="ref-vol">33</span>:779–82.</span> [<a href="/pmc/articles/PMC1050735/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1050735</span></a>] [<a href="/pubmed/8880581" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8880581</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.mulligan.1994.2163">Mulligan LM, Eng C, Atti&#x000e9; T, Lyonnet S, Marsh DJ, Hyland VJ, Robinson BG, Frilling A, Verellen-Dumoulin C, Safar A, Venter D, Munnich A, Ponder B. Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. <span><span class="ref-journal">Hum Mol Genet. </span>1994;<span class="ref-vol">3</span>:2163–7.</span> [<a href="/pubmed/7881414" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7881414</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF90">National Comprehensive Cancer Network. Guidelines for the treatment of thyroid carcinoma. NCCN website. 2015.</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.neumann.2002.1459">Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Pe&#x000e7;zkowska M, Szmigielski C, Eng C, et al.  Germ-line mutations in nonsyndromic pheochromocytoma. <span><span class="ref-journal">N Engl J Med. </span>2002;<span class="ref-vol">346</span>:1459–66.</span> [<a href="/pubmed/12000816" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12000816</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.neumann.2009.3650">Neumann HP, Erlic Z, Boedeker CC, Rybicki LA, Robledo M, Hermsen M, Schiavi F, Falcioni M, Kwok P, Bauters C, Lampe K, Fischer M, Edelman E, Benn DE, Robinson BG, Wiegand S, Rasp G, Stuck BA, Hoffmann MM, Sullivan M, Sevilla MA, Weiss MM, Peczkowska M, Kubaszek A, Pigny P, Ward RL, Learoyd D, Croxson M, Zabolotny D, Yaremchuk S, Draf W, Muresan M, Lorenz RR, Knipping S, Strohm M, Dyckhoff G, Matthias C, Reisch N, Preuss SF, Esser D, Walter MA, Kaftan H, St&#x000f6;ver T, Fottner C, Gorgulla H, Malekpour M, Zarandy MM, Schipper J, Brase C, Glien A, K&#x000fc;hnemund M, Koscielny S, Schwerdtfeger P, V&#x000e4;lim&#x000e4;ki M, Szyfter W, Finckh U, Zerres K, Casc&#x000f3;n A, Opocher G, Ridder GJ, Januszewicz A, Suarez C, Eng C. Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. <span><span class="ref-journal">Cancer Res. </span>2009;<span class="ref-vol">69</span>:3650–6.</span> [<a href="/pubmed/19351833" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19351833</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.neumann.2004.943">Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C, et al.  Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. <span><span class="ref-journal">JAMA. </span>2004;<span class="ref-vol">292</span>:943–51.</span> [<a href="/pubmed/15328326" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15328326</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.neumann.2011.e1279">Neumann HP, Sullivan M, Winter A, Malinoc A, Hoffmann MM, Boedeker CC, Engelhardt M, Walz MK, Eng C. Germline mutations of the TMEM127 genes in patients with paraganglioma of the head and neck and extra-adrenal abdominal sites. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2011;<span class="ref-vol">96</span>:E1279–82.</span> [<a href="/pubmed/21613359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21613359</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.neumann.2019.552">Neumann HP, Young WF Jr, Eng C. Pheochromocytoma and paraganglioma. <span><span class="ref-journal">N Engl J Med. </span>2019;<span class="ref-vol">381</span>:552–65.</span> [<a href="/pubmed/31390501" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31390501</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.nguyen.2001.37">Nguyen L, Niccoli-Sire P, Caron P, Bastie D, Maes B, Chabrier G, Chabre O, Rohmer V, Lecomte P, Henry JF, Conte-Devolx B, et al.  Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study. <span><span class="ref-journal">Eur J Endocrinol. </span>2001;<span class="ref-vol">144</span>:37–44.</span> [<a href="/pubmed/11174835" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11174835</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.niccolisire.2003.1029">Niccoli-Sire P, Murat A, Rohmer V, Gibelin H, Chabrier G, Conte-Devolx B, Visset J, Ronceray J, Jaeck D, Henry JF, Proye C, Carnaille B, Kraimps JL, et al.  When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations? <span><span class="ref-journal">Surgery. </span>2003;<span class="ref-vol">134</span>:1029–36.</span> [<a href="/pubmed/14668737" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14668737</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.nilsson.1999.1587">Nilsson O, Tisell LE, Jansson S, Ahlman H, Gimm O, Eng C. Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation. <span><span class="ref-journal">JAMA. </span>1999;<span class="ref-vol">281</span>:1587–8.</span> [<a href="/pubmed/10235148" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10235148</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.nunes.2002.5658">Nunes AB, Ezabella MC, Pereira AC, Krieger JE, Toledo SP. A novel Val648Ile substitution in RET protooncogene observed in a Cys634Arg multiple endocrine neoplasia type 2A kindred presenting with an adrenocorticotropin-producing pheochromocytoma. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2002;<span class="ref-vol">87</span>:5658–61.</span> [<a href="/pubmed/12466368" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12466368</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.pacak.2005.60">Pacak K, Ilias I, Adams KT, Eisenhofer G. Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. <span><span class="ref-journal">J Intern Med. </span>2005;<span class="ref-vol">257</span>:60–8.</span> [<a href="/pubmed/15606377" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15606377</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.peczkowska.2008.111">Peczkowska M, Casc&#x000f3;n A, Prejbisz A, Kubaszek A, Cwik&#x00142;a BJ, Furmanek M, Erlic Z, Eng C, Januszewicz A, Neumann HP. Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. <span><span class="ref-journal">Nat Clin Pract Endocrinol Metab. </span>2008;<span class="ref-vol">4</span>:111–5.</span> [<a href="/pubmed/18212813" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18212813</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.pigny.1999.1700">Pigny P, Bauters C, Wemeau JL, Houcke ML, Crepin M, Caron P, Giraud S, Calender A, Buisine MP, Kerckaert JP, Porchet N. A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>1999;<span class="ref-vol">84</span>:1700–4.</span> [<a href="/pubmed/10323403" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10323403</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.pomares.1998.195">Pomares FJ, Ca&#x000f1;as R, Rodriguez JM, Hernandez AM, Parrilla P, Tebar FJ. Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>1998;<span class="ref-vol">48</span>:195–200.</span> [<a href="/pubmed/9579232" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9579232</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.pu_ales.2003.2644">Pu&#x000f1;ales MK, Graf H, Gross JL, Maia AL. RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2003;<span class="ref-vol">88</span>:2644–9.</span> [<a href="/pubmed/12788868" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12788868</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.puxeddu.2003.505">Puxeddu E, Moretti S, Giannico A, Martinelli M, Marino C, Avenia N, Cristofani R, Farabi R, Reboldi G, Ribacchi R, Pontecorvi A, Santeusanio F. Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. <span><span class="ref-journal">Eur J Endocrinol. </span>2003;<span class="ref-vol">148</span>:505–13.</span> [<a href="/pubmed/12720532" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12720532</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.qin.2010.229">Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, Lechleiter JD, Sass M, Aronin N, Schiavi F, Boaretto F, Opocher G, Toledo RA, Toledo SP, Stiles C, Aguiar RC, Dahia PL. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. <span><span class="ref-journal">Nat Genet. </span>2010;<span class="ref-vol">42</span>:229–33.</span> [<a href="/pmc/articles/PMC2998199/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2998199</span></a>] [<a href="/pubmed/20154675" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20154675</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.remacha.2018.1644">Remacha L, Curras-Freixes M, Torres-Ruiz R, Schiavi F, Torres-P&#x000e9;rez R, Calsina B, Let&#x000f3;n R, Comino-M&#x000e9;ndez I, Rold&#x000e1;n-Romero JM, Montero-Conde C, Santos M, P&#x000e9;rez LI, Pita G, Alonso MR, Honrado E, Pedrinaci S, Crespo-Facorro B, Percesepe A, Falcioni M, Rodr&#x000ed;guez-Perales S, Korpershoek E, Ram&#x000f3;n-Maiques S, Opocher G, Rodr&#x000ed;guez-Antona C, Robledo M, Casc&#x000f3;n A. Gain-of-function mutations in DNMT3A in patients with paraganglioma. <span><span class="ref-journal">Genet Med. </span>2018;<span class="ref-vol">20</span>:1644–51.</span> [<a href="/pubmed/29740169" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29740169</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.rey.2001.390">Rey JM, Brouillet JP, Fonteneau-Allaire J, Boneu A, Basti&#x000e9; D, Maudelonde T, Pujol P. Novel germline RET mutation segregating with papillary thyroid carcinomas. <span><span class="ref-journal">Genes Chromosomes Cancer. </span>2001;<span class="ref-vol">32</span>:390–1.</span> [<a href="/pubmed/11746981" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11746981</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.robledo.2003.1814">Robledo M, Gil L, Poll&#x000e1;n M, Cebri&#x000e1;n A, Ru&#x000ed;z S, Aza&#x000f1;edo M, Benitez J, Men&#x000e1;rguez J, Rojas JM. Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. <span><span class="ref-journal">Cancer Res. </span>2003;<span class="ref-vol">63</span>:1814–7.</span> [<a href="/pubmed/12702567" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12702567</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.rodriguez.2008.2520">Rodriguez JM, Balsalobre M, Ponce JL, R&#x000ed;os A, Torregrosa NM, Tebar J, Parrilla P. Pheochromocytoma in MEN 2A syndrome. Study of 54 patients. <span><span class="ref-journal">World J Surg. </span>2008;<span class="ref-vol">32</span>:2520–6.</span> [<a href="/pubmed/18795243" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18795243</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.romeo.1998.515">Romeo G, Ceccherini I, Celli J, Priolo M, Betsos N, Bonardi G, Seri M, Yin L, Lerone M, Jasonni V, Martucciello G. Association of multiple endocrine neoplasia type 2 and Hirschsprung disease. <span><span class="ref-journal">J Intern Med. </span>1998;<span class="ref-vol">243</span>:515–20.</span> [<a href="/pubmed/9681852" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9681852</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.rothberg.2009.651">Rothberg AE, Raymond VM, Gruber SB, Sisson J. Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis. <span><span class="ref-journal">Thyroid. </span>2009;<span class="ref-vol">19</span>:651–5.</span> [<a href="/pubmed/19445625" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19445625</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.ruiz.2001.399">Ruiz A, Anti&#x000f1;olo G, Fern&#x000e1;ndez RM, Eng C, Marcos I, Borrego S. Germline sequence variant S836S in the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2001;<span class="ref-vol">55</span>:399–402.</span> [<a href="/pubmed/11589684" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11589684</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.santoro.2004.5448">Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. Minireview: RET: normal and abnormal functions. <span><span class="ref-journal">Endocrinology. </span>2004;<span class="ref-vol">145</span>:5448–51.</span> [<a href="/pubmed/15331579" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15331579</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.santoro.2002.370">Santoro M, Papotti M, Chiappetta G, Garcia-Rostan G, Volante M, Johnson C, Camp RL, Pentimalli F, Monaco C, Herrero A, Carcangiu ML, Fusco A, Tallini G. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2002;<span class="ref-vol">87</span>:370–9.</span> [<a href="/pubmed/11788678" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11788678</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.schilling.2001.62">Schilling T, B&#x000fc;rck J, Sinn HP, Clemens A, Otto HF, H&#x000f6;ppner W, Herfarth C, Ziegler R, Schwab M, Raue F. Prognostic value of codon 918 (ATG--&#x0003e;ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. <span><span class="ref-journal">Int J Cancer. </span>2001;<span class="ref-vol">95</span>:62–6.</span> [<a href="/pubmed/11241313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11241313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.schuffenecker.1997.233">Schuffenecker I, Ginet N, Goldgar D, Eng C, Chambe B, Boneu A, Houdent C, Pallo D, Schlumberger M, Thivolet C, Lenoir GM. Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine. <span><span class="ref-journal">Am J Hum Genet. </span>1997;<span class="ref-vol">60</span>:233–7.</span> [<a href="/pmc/articles/PMC1712555/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1712555</span></a>] [<a href="/pubmed/8981969" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8981969</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.schulte.2010.e92">Schulte KM, Machens A, Fugazzola L, McGregor A, Diaz-Cano S, Izatt L, Aylwin S, Talat N, Beck-Peccoz P, Dralle H. The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2010;<span class="ref-vol">95</span>:E92–7.</span> [<a href="/pubmed/20554711" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20554711</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.seri.1997.86">Seri M, Celli I, Betsos N, Claudiani F, Camera G, Romeo G. A. Cys634Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis. <span><span class="ref-journal">Clin Genet. </span>1997;<span class="ref-vol">51</span>:86–90.</span> [<a href="/pubmed/9111993" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9111993</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.shifrin.2009.998">Shifrin AL, Xenachis C, Fay A, Matulewicz TJ, Kuo YH, Vernick JJ. One hundred and seven family members with the rearranged during transfection V804M proto-oncogene mutation presenting with simultaneous medullary and papillary thyroid carcinomas, rare primary hyperparathyroidism, and no pheochromocytomas: is this a new syndrome--MEN 2C? <span><span class="ref-journal">Surgery. </span>2009;<span class="ref-vol">146</span>:998–1005.</span> [<a href="/pubmed/19958926" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19958926</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.skinner.1996.177">Skinner MA, DeBenedetti MK, Moley JF, Norton JA, Wells SA Jr. Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. <span><span class="ref-journal">J Pediatr Surg. </span>1996;<span class="ref-vol">31</span>:177–81.</span> [<a href="/pubmed/8632274" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8632274</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.smith.1997.1213">Smith DP, Houghton C, Ponder BA. Germline mutation of RET codon 883 in two cases of de novo MEN 2B. <span><span class="ref-journal">Oncogene. </span>1997;<span class="ref-vol">15</span>:1213–7.</span> [<a href="/pubmed/9294615" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9294615</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.subbiah.2018.836">Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK. Precision targeted therapy with BLU-667 for RET-driven cancers. <span><span class="ref-journal">Cancer Discov. </span>2018;<span class="ref-vol">8</span>:836–49.</span> [<a href="/pubmed/29657135" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29657135</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.szinnai.2003.e132">Szinnai G, Meier C, Komminoth P, Zumsteg UW. Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. <span><span class="ref-journal">Pediatrics. </span>2003;<span class="ref-vol">111</span>:E132–9.</span> [<a href="/pubmed/12563086" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12563086</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.ta_eb.2013.e908">Ta&#x000ef;eb D, Yang C, Delenne B, Zhuang Z, Barlier A, Sebag F, Pacak K. First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2013;<span class="ref-vol">98</span>:E908–13.</span> [<a href="/pmc/articles/PMC3644612/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3644612</span></a>] [<a href="/pubmed/23539726" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23539726</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.takahashi.1998.509">Takahashi M, Asai N, Iwashita T, Murakami H, Ito S. Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations. <span><span class="ref-journal">J Intern Med. </span>1998;<span class="ref-vol">243</span>:509–13.</span> [<a href="/pubmed/9681851" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9681851</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.takahashi.1999.331">Takahashi M, Iwashita T, Santoro M, Lyonnet S, Lenoir GM, Billaud M. Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function? <span><span class="ref-journal">Hum Mutat. </span>1999;<span class="ref-vol">13</span>:331–6.</span> [<a href="/pubmed/10220148" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10220148</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.takaya.1996.617">Takaya K, Yoshimasa T, Arai H, Tamura N, Miyamoto Y, Itoh H, Nakao K. Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin. <span><span class="ref-journal">J Mol Med (Berl). </span>1996;<span class="ref-vol">74</span>:617–21.</span> [<a href="/pubmed/8912182" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8912182</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.tallini.1998.287">Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML, Fusco A. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. <span><span class="ref-journal">Clin Cancer Res. </span>1998;<span class="ref-vol">4</span>:287–94.</span> [<a href="/pubmed/9516913" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9516913</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.thosani.2013.e1813">Thosani S, Ayala-Ramirez M, Palmer L, Hu MI, Rich T, Gagel RF, Cote G, Waguespack SG, Habra MA, Jimenez C. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2013;<span class="ref-vol">98</span>:E1813–9.</span> [<a href="/pmc/articles/PMC5399523/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5399523</span></a>] [<a href="/pubmed/24030942" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24030942</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.vandy.2011.805">Vandy FC, Sisk G, Berguer R. Synchronous carotid body and thoracic paraganglioma associated with a germline SDHC mutation. <span><span class="ref-journal">J Vasc Surg. </span>2011;<span class="ref-vol">53</span>:805–7.</span> [<a href="/pubmed/21106325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21106325</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.verga.2003.156">Verga U, Fugazzola L, Cambiaghi S, Pritelli C, Alessi E, Cortelazzi D, Gangi E, Beck-Peccoz P. Frequent association between MEN 2A and cutaneous lichen amyloidosis. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2003;<span class="ref-vol">59</span>:156–61.</span> [<a href="/pubmed/12864791" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12864791</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.welander.2011.r253">Welander J, S&#x000f6;derkvist P, Gimm O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. <span><span class="ref-journal">Endocr Relat Cancer. </span>2011;<span class="ref-vol">18</span>:R253–76.</span> [<a href="/pubmed/22041710" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22041710</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.wells.2015.567">Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG, et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. <span><span class="ref-journal">Thyroid. </span>2015;<span class="ref-vol">25</span>:567–610.</span> [<a href="/pmc/articles/PMC4490627/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4490627</span></a>] [<a href="/pubmed/25810047" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25810047</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.wells.2013.3149">Wells SA Jr, Pacini F, Robinson BG, Santoro M. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2013;<span class="ref-vol">98</span>:3149–64.</span> [<a href="/pmc/articles/PMC5399478/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5399478</span></a>] [<a href="/pubmed/23744408" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23744408</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.wray.2008.293">Wray CJ, Rich TA, Waguespack SG, Lee JE, Perrier ND, Evans DB. Failure to recognize multiple endocrine neoplasia 2B: more common than we think? <span><span class="ref-journal">Ann Surg Oncol. </span>2008;<span class="ref-vol">15</span>:293–301.</span> [<a href="/pubmed/17963006" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17963006</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.yang.2015.93">Yang C, Zhuang Z, Fliedner SM, Shankavaram U, Sun MG, Bullova P, Zhu R, Elkahloun AG, Kourlas PJ, Merino M, Kebebew E, Pacak K. Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. <span><span class="ref-journal">J Mol Med (Berl). </span>2015;<span class="ref-vol">93</span>:93–104.</span> [<a href="/pubmed/25263965" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25263965</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.yao.2010.2611">Yao L, Schiavi F, Casc&#x000f3;n A, Qin Y, Inglada-P&#x000e9;rez L, King EE, Toledo RA, Ercolino T, Rapizzi E, Ricketts CJ, Mori L, Giacch&#x000e8; M, Mendola A, Taschin E, Boaretto F, Loli P, Iacobone M, Rossi GP, Biondi B, Lima-Junior JV, Kater CE, Bex M, Vikkula M, Grossman AB, Gruber SB, Barontini M, Persu A, Castellano M, Toledo SP, Maher ER, Mannelli M, Opocher G, Robledo M, Dahia PL. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. <span><span class="ref-journal">JAMA. </span>2010;<span class="ref-vol">304</span>:2611–9.</span> [<a href="/pubmed/21156949" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21156949</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.yip.2003.409">Yip L, Cote GJ, Shapiro SE, Ayers GD, Herzog CE, Sellin RV, Sherman SI, Gagel RF, Lee JE, Evans DB. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. <span><span class="ref-journal">Arch Surg. </span>2003;<span class="ref-vol">138</span>:409–16.</span> [<a href="/pubmed/12686527" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12686527</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="men2.REF.zbuk.2007.35">Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. <span><span class="ref-journal">Nat Rev Cancer. </span>2007;<span class="ref-vol">7</span>:35–45.</span> [<a href="/pubmed/17167516" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17167516</span></a>]</div></li></ul></div></div><div id="men2.Chapter_Notes"><h2 id="_men2_Chapter_Notes_">Chapter Notes</h2><div id="men2.Author_History"><h3>Author History</h3><p>Charis Eng, MD, PhD, FACP (2010-present)<br />Jessica Marquard, MS, LGC; Cleveland Clinic (2010-2019)<br />Karen Snow-Bailey, PhD, FACMG, FHGSA; Auckland City Hospital (1999-2006*)<br />Georgia L Wiesner, MD, MS, FACMG; Case Western Reserve University School of Medicine (1999-2010)</p><p>*Karen Snow-Bailey died on September 10, 2006. The following is excerpted from a tribute by Stephen N Thibodeau, PhD, of the Mayo Clinic, Rochester, MN:</p><p>"Karen was well known to so many of us, as she was an active member of the Association for Molecular Pathology (AMP)....In 1993, Karen joined the medical staff at the Mayo Clinic, where she was responsible for codirecting the Molecular Genetics Laboratory in the Department of Laboratory Medicine and Pathology....In 2002, Karen returned to New Zealand to be closer to family and became an international presence. Importantly, she began to have a tremendous influence in the development of diagnostic genetics services both in New Zealand and Australia....Karen was a scientist, an educator, and an artist....We will all miss Karen as a colleague, as a mentor to many, as an individual who had a vision for the future, but most importantly, as a warm and compassionate friend who cared for others."</p><p>[Reprinted from <i>J Mol Diagn</i> 2007, 9:133 with permission from the American Society for Investigative Pathology and the Association for Molecular Pathology]</p></div><div id="men2.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>15 August 2019 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 June 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>10 January 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>4 May 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 March 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 May 2004 (cd) Revision: Genetic Counseling</div></li><li class="half_rhythm"><div>21 January 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>27 September 1999 (me) Review posted live</div></li><li class="half_rhythm"><div>October 1998 (gw) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1257</span><span class="label">PMID: <a href="/pubmed/20301434" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301434</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/men1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/edm-ad/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1257&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1257/?report=reader">PubReader</a></li><li><a href="/books/NBK1257/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1257" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1257" style="display:none" title="Cite this Page"><div class="bk_tt">Eng C. Multiple Endocrine Neoplasia Type 2. 1999 Sep 27 [Updated 2019 Aug 15]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1257/pdf/Bookshelf_NBK1257.pdf">PDF version of this page</a> (630K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#men2.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#men2.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#men2.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#men2.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#men2.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#men2.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#men2.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#men2.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#men2.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#men2.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#men2.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#men2.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5979[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">RET</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4914[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">NTRK1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1461420" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1461420" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1461420" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1461420" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15233908" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Multiple endocrine neoplasia type 2.</a><span class="source">[Curr Treat Options Oncol. 2004]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Multiple endocrine neoplasia type 2.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Gertner ME, Kebebew E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Curr Treat Options Oncol. 2004 Aug; 5(4):315-25. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/8632274" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B.</a><span class="source">[J Pediatr Surg. 1996]</span><div class="brieflinkpop offscreen_noflow">Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Skinner MA, DeBenedetti MK, Moley JF, Norton JA, Wells SA Jr. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Pediatr Surg. 1996 Jan; 31(1):177-81; discussion 181-2. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/9167949" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.</a><span class="source">[Horm Res. 1997]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Marsh DJ, Mulligan LM, Eng C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Horm Res. 1997; 47(4-6):168-78. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/9074721" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [Neural crest and multiple endocrinopathies].</a><span class="source">[C R Seances Soc Biol Fil. 1996]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [Neural crest and multiple endocrinopathies].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pasini A, Michiels FM, Chappuis-Flament S, Geneste O, Rossel M, Fournier L, Feunteun J, Lenoir G, Schuffenecker I, Billaud M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">C R Seances Soc Biol Fil. 1996; 190(5-6):557-67. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/12746565" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation.</a><span class="source">[Endocr Pathol. 2003]</span><div class="brieflinkpop offscreen_noflow">Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">González-Yebra B, Medrano ME, Mantilla A, Palma V, Colin C, Hernández DM, Tapia J, Dawson B, Salcedo M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Endocr Pathol. 2003 Spring; 14(1):71-80. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301434" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301434" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04191ddde0891169459077">Multiple Endocrine Neoplasia Type 2 - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Multiple Endocrine Neoplasia Type 2 - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:21:17-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal104&amp;ncbi_phid=CE8BAF46E0404AB100000000088902FE&amp;ncbi_session=CE8BAF46E04191C1_2185SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1257%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1257&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1257/&amp;ncbi_pagename=Multiple Endocrine Neoplasia Type 2 - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8BAF46E04191C1_2185SID /projects/books/PBooks@5.22 portal104 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>